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Abbreviation  III 
 
Abbreviation  
ARMS    allele-specific tetra-primer amplification refractory mutation system 
ASTQ    allele-specific transcript quantification 
CD14    cluster of differentiation protein 14 
cDNA     complementary DNA 
CDK     cyclin dependent kinase 
CpG-DNA   cytosine-phosphate-guanine-DNA 
CTD     carboxyl-terminal domain 
DC     dendritic cell  
dsRNA    double-stranded  
EMSA    electrophoretic mobility shift assay 
gDNA    genomic DNA 
GPI     glycosyl phosphatidylinositol  
HaploChIP    haplotype-specific chromatin immunoprecipitation 
HCV     hepatitis C virus  
HWE     Hardy-Weinberg equilibrium 
IFN     interferon 
IKK     IκB kinase 
IL     interleukin  
IRAK     interleukin 1 receptor associated kinase  
IRF    interferon regulatory factor 
LD     linkage disequilibrium  
LPS     lipopolysaccharide  
LBP     LPS-binding protein 
MAF     minor allele frequency  
Med     mediator complex 
mCD14   membrane CD14 
MD2    myeloid differentiation protein 2 
mRNA    messenger RNA 
MyD88   myeloid differentiation factor 88 
NF    nuclear factor 
NK     natural killer 
PAMP    pathogen-associated molecular pattern  
PBMC    peripheral blood mononuclear cell  
Abbreviation  IV 
 
PCR     polymerase chain reaction  
pDC     plasmacytoid DC 
Pro     proline 
PRR     pathogen recognition receptor 
RNAPII   RNA polymerase II 
RFLP     restriction fragment length polymorphism 
rSNP     regulatory SNP  
sCD14    soluble CD14  
Ser     serine 
ser2-P/ser5-P   serine 2 / serine 5 phosphorylated 
SNP     single nucleotide polymorphism  
SNRPN    small nuclear ribonucleoprotein polypeptide N  
ssRNA    single-stranded RNA  
TFII     transcription factor II  
Thr     threonine 
TIR    Toll/interleukin 1 receptor 
TIRAP    TIR domain containing adaptor protein 
TLR    Toll-like receptor 
TNF     tumor necrosis factor  
TRAM   TIR domain containing adaptor molecule 
TRIF    TIR domain containing adaptor inducing IFN-β 
Tyr     tyrosine 




1.1. Innate immune system 
The human host defence serves two main functions, (i) to generate immune response to invading 
pathogens and (ii) to suppress development of tumor cells (Tamura et al., 2008). The immune 
system has been traditionally divided into the innate and the adaptive part. While the adaptive 
component is organized in two specialized cell classes, T cells and B cells, that provide a very large 
and extremely diverse repertoire of antigen receptors, the effector mechanisms of the innate part of 
host immunity are activated immediately after infection and rapidly control the replication of the 
infecting pathogen (Medzhitov and Janeway, 2000). Recognition of invading pathogens is 
dependent on a limited number of pathogen recognition receptors (PRRs) that recognize pathogen-
associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS) or viral nucleic acids 
(1.1.1). Signal transduction activated by these PRRs induces various target genes including type I 
interferons (IFNs), proinflammatory cytokines and chemokines. To carry out this task of cellular 
response a genetic regulatory network controlled by a specific set of transcription factors dependent 
on cell type and/or cellular stimuli is provided by the innate immune system (Akira et al., 2006; 
Szabo et al., 2006; Tamura et al., 2008). The functional diversity of transcription factors is 
dependent on its modification and/or interaction with other transcription factors activated in the 
same cell type and such regulatory networks are critical for host defence against extracellular 
pathogens as they rapidly alter the expression of relevant genes (Taniguchi et al., 2001). 
 
1.1.1. PRRs  
Invading pathogens are detected by PRRs, which recognize highly conserved structures only 
produced by microorganisms, like LPS, peptidoglucan, lipoteichoic acids, double-stranded RNA 
(dsRNA) and glucans. The PRRs are germ-line-encoded receptors which mean that their specificity 
for the classes of infectious pathogens is genetically predetermined. The expression of these 
receptors is not clonal. This fact accounts for the rapid kinetics of the innate immune response, thus 
once an effector cell identifies PAMPs the effector function can be performed immediately and not 
after proliferation of the acting cell (Medzhitov and Janeway, 2000; Szabo et al., 2006).  
PRRs can be classified by structure or by function. Structurally, these receptors belong to several 
protein families, such as leucine-rich repeat domains, calcium-dependent lectin domains and 
scavenger-receptor protein domains. Functionally, PRRs can be divided into three classes: secreted, 
endocytic and signalling (Medzhitov and Janeway, 2000).  
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On recognizing the pathogens, secreted PRRs flag the microbial cell for the complement system and 
phagocytes, endocytic PRRs mediate the uptake and delivery of the pathogens into lysosomes and 
signalling receptors activate signal-transduction pathways that induce the expression of a variety of 
immune-response genes (Medzhitov and Janeway, 2000).  
 
1.1.2. Toll-like receptors (TLRs) 
The Toll-like receptor (TLR) family is the best characterized class of PRRs in mammals and the 
number of TLR genes ranges between 10 and 15 in most mammalian species (Iwasaki and 
Medzhitov, 2004). TLRs are widely expressed on immune cells and recognition of PAMPs induces 
a prompt and potent innate immune response signalled through adaptor molecules, like myeloid 
differentiation factor 88 (MyD88), to activate transcription factors like nuclear factor (NF)-κB or 
interferon regulatory factors (IRFs) that induce expression of antibacterial or antiviral response 
genes.  
TLR1, TLR2, TLR4-6 are expressed on the cell surface and TLR3, TLR7-9 are located on the 
endosome-lysosome membrane. TLR1, TLR2 and TLR6 recognize bacterial lipopeptides while 
TLR4 and TLR5 are receptors for Gram-negative bacterial cell wall components such as LPS or 
flagellin, respectively. Intracellular TLRs detect viral-derived or synthetic dsRNA and viral-related 
single-stranded RNA (ssRNA) and unmethylated cytosine-phosphate-guanine DNA (CpG-DNA) of 
bacteria and viruses (Fig. 1), but ligands of TLR10, TLR12 and TLR13 are still unidentified 














Figure 1: TLRs and their ligands  
TLR2 is essential in the recognition of microbial 
lipopeptides. TLR1 and TLR6 cooperate with 
TLR2 to discriminate subtle differences between 
triacyl and diacyl lipopeptides, respectively. 
TLR4 is the receptor for LPS. TLR9 is essential 
in CpG-DNA recognition. TLR3 is implicated in 
the recognition of viral dsRNA, whereas TLR7 
and TLR8 are involved in viral-derived ssRNA 
recognition (Alexopoulou et al., 2001; Heil et al., 
2004; Takeda and Akira, 2005). TLR5 recognizes 
flagellin (From Takeda and Akira, 2005).  
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1.1.3. TLR expression in different cell types 
The epithelial layer provides the first line of defence against invading pathogens. As a consequence, 
many TLRs are expressed on epithelial cells of the intestinal, respiratory and urogenital tracts. 
Microbial detecting by TLRs expressed by these cells leads to production of cytokines, chemokines 
and antimicrobial peptides (Iwasaki and Medzhitov, 2004). Many types of PRRs are expressed by 
dendritic cells (DCs), including C-type lectins, mannose receptors and TLRs. Studies of DC subsets 
revealed that TLRs have distinct expression patterns and there are also distinct differences in 
expression and responsiveness of certain TLRs in freshly isolated DCs versus in vitro-derived DCs.  
Plasmacytoid DCs (pDCs) express TLR7 and TLR9, whereas myeloid DCs (mDCs) express TLR1-
3, TLR5, TLR6 and TLR8. Human blood monocytes express TLR1, 2, 4 and 5. Only monocytes 
and in vitro-differentiated DCs express TLR4 and respond thus to LPS stimulation (Iwasaki and 
Medzhitov, 2004).  
TLRs are also expressed by liver cells. Hepatic pDCs also produce tumor necrosis factor (TNF) -α, 
interleukin (IL) -6 and IL-12 by TLR7 and TLR9 stimulation. In general, hepatic DCs are 
hyperresponsive to TLR ligands. Kupffer cells are the first cells to encounter gut-derived toxins 
including LPS, thus TLR4 signalling drives Kupffer cells to produce TNF-α, IL-6, -12, -18 and 
anti-inflammatory cytokine IL-10. IL-12 and IL-18 activate hepatic natural killer (NK) cells to 
increase the synthesis and release of antimicrobial IFN-γ. Kupffer cells also express TLR2, TLR3 
and TLR9. Hepatocytes express a very low level of TLR2-5 and their responses are fairly weak in 
vivo. Hepatic stellate cells (HSCs) express TLR4 and TLR9, while TLR2-5 are expressed by biliary 
epithelial cells (Seki and Brenner, 2008).  
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1.1.4. TLR signalling pathways 
All TLR members, except TLR3, are associated with the common adaptor molecule MyD88 to 
trigger inflammatory response such as TNF-α and IL-12. TLR3 and TLR4 utilize the 
Toll/interleukin-1 receptor (TIR) domain containing the adapter-inducing IFN-β (TRIF) molecule to 
induce type I IFN. TLR signalling pathways are MyD88-dependent or MyD88-independent/TRIF-
dependent (Fig. 2). The MyD88-dependet pathway leads to activation of the transcription factor 
NF-κB and induces expression of inflammatory cytokines like TNF-α, IL-6 and IL-12. TLR3 and 
TLR4 utilize the MyD88-independent component to induce IFN-β. Here, TRIF is used to activate 
an inhibitor of NF-κB, which leads to activation of IRF-3 followed by IFN-β production (Armant 

























Figure 2: TLR signalling pathways 
TLR signalling pathways originate from the cytoplasmic TIR domain. A TIR domain-containing adaptor, MyD88, 
associates with the cytoplasmic TIR domain of TLRs, and recruits IL-1 receptor-associated kinase (IRAK) to the 
receptor upon ligand binding. IRAK then activates tumor necrosis receptor-associated factor (TRAF)-6, leading to the 
activation of the inhibitor of NFκB (IκB) kinase (IKK) complex which consists of IKKα, IKKβ and NFκB essential 
modulator (NEMO)/IKKγ. The IKK complex phosphorylates IκB and results in nuclear translocation of NF-κB which 
induces expression of inflammatory cytokines. A second TIR domain containing adaptor protein (TIRAP), is involved 
in the MyD88-dependent signalling pathway via TLR2 and TLR4. In TLR3- and TLR4-mediated signalling pathways, 
activation of IRF-3 and induction of IFN-β are observed in a MyD88-independent manner. A third TIR domain-
containing adaptor, TRIF, is essential for the MyD88-independent pathway. Non-typical IKKs, IKKi/IKKε and the 
threonine protein kinase 1 (TBK1) mediate the activation of IRF-3 downstream of TRIF. A fourth TIR domain-
containing adaptor molecule (TRAM) is specific to the TLR4-mediated MyD88-independent/TRIF-dependent pathway 
(From Takeda and Akira, 2005).  
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1.1.5. TLR4-MD2-CD14 complex and LPS 
LPS is recognized by a receptor complex of TLR4, myeloid differentiation protein 2 (MD2) and the 
cluster of differentiation protein 14 (CD14), which are present on many mammalian cell types 
including macrophages and DCs (Miller et al., 2005; Seki and Brenner, 2008). Recognition of lipid 
A (endotoxin), a LPS component (Fig. 3a), requires an accessory protein, the LPS-binding protein 
(LBP), which delivers LPS to CD14, a high-affinity, glycosyl phosphatidylinositol (GPI)-anchored 
membrane protein that can also circulate in a soluble form. CD14 concentrates LPS for binding to 
the TLR4-MD2 complex (Fig. 3b). Upon binding of LPS, the intracellular domain of TLR4 recruits 
TIRAP and MyD88 for MyD88-dependent signalling, resulting in activation of NF-κB, while 
TRAM bridges TRIF for the MyD88-independent pathway to activate IRF-3 which induces type I 
IFN expression (Fig. 2) (Beutler, 2009; Godowski, 2005; Palsson-McDermott and O'Neill, 2004; 
Seki and Brenner, 2008). 
Although lipid A is an essential component of all Gram-negative bacterial membranes, it is highly 
diverse. Number and length of fatty-acid sides of lipid A were observed to be manifold and this 
variability could have profound implications for disease, particularly in humans, owing to an altered 
recognition by the TLR4 complex. In fact, structure-function analyses have indicated that number 
and length of acid side chains are critical for TLR4 signalling in humans (Miller et al., 2005). 
Humans evolved discriminatory mechanisms for different lipid A structures which could result in 
different infection disease outcomes. It was shown that the extracellular domain of TLR4 is less 
conserved than the cytoplasmatic signalling domain and that there is also a hypervariable 
extracellular domain (Fig. 3b) that can discriminate between different lipid A structures (Miller et 













Figure 3: Structure of LPS and TLR4 
(a) LPS is composed of lipid A, core oligosaccharide 
and O-antigen. (b) Components of the TLR4–MD2–
CD14 receptor complex. Different TLR4 regions are 
shown: leucine-rich repeats (LLRs), a hypervariable 
region (HYP) and the intracellular TIR domain. 
Membrane bound CD14 with a GPI-anchor (From Miller 
et al., 2005).  
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1.1.6. CD14 
CD14 is present on the surface of different myeloid cells and at very low numbers on B-
lymphocytes, basophils, mammary cells, placental trophoblasts and gingival fibroblasts. Although 
CD14 is not a transmembrane protein, but is attached to the plasma membrane via the GPI tail, 
there exists also a soluble CD14 (sCD14) molecule which is found in normal human serum and in 
culture supernatants of human monocytes and cell lines (Antal-Szalmas, 2000). The sCD14s have 
an important role in LPS-mediated activation of CD14-negative (but TLR4-positive) cells, like 
epithelial and smooth muscle cells (Arroyo-Espliguero et al., 2004; Palsson-McDermott and 
O'Neill, 2004). Differentiation of monocytes, in tissues, into macrophages is accompanied by a 
change in membrane CD14 (mCD14) numbers. The synthesis and expression of CD14 in 
monocytes, macrophages and neutrophils can be altered and regulated by several mediators. In 
neutrophils, TNF-α and LPS are known to rapidly upregulate CD14 expression, while in 
monocytes, expression is decreased by the anti-inflammatory cytokines IL-4 and IL-13 (Antal-
Szalmas, 2000).  
As mentioned before, CD14 is part of the multiprotein complex TLR4-MD2-CD14 and thus acts as 
a pattern recognition molecule that has a central role in innate immunity. It can interact in a non-
specific fashion with several ligands, including LPS from Gram-negative bacteria and components 
from Gram-positive bacteria and fungi. Both mCD14 and sCD14, together with LBP, are the first 
line screeners of microbial antigens and present them to the more pathogen-specific signalling 
receptor TLR4-MD2 (Arroyo-Espliguero et al., 2004; Kitchens and Thompson, 2005). 
 
1.1.7. IRF-1 
The IRF family was identified in the late 1980s and consists of nine members in mammals. This 
family was the first identified transcriptional regulators of type I IFN and IFN-inducible genes and 
is now recognized as playing a critical part in innate and adaptive immunity (Honda and Taniguchi, 
2006; Tamura et al., 2008). Many IRF members (IRF-1, IRF-3, IRF-5 and IRF-8) play a central role 
in cell growth, cell survival and oncogenesis, as well as in the regulation of gene expression in 
response to pathogen infection (IRF-1, IRF-3, IRF-4, IRF-5, IRF-7 and IRF-8) (Tamura et al., 
2008). In fact, IRF-1 is suggested to provide a link between the innate and adaptive immune system. 
First of all, IRF-1 induces many genes involved in the initial reaction to pathogen infection such as 
2´-, 5´- oligo adenylate synthetase (OAS), protein kinase R (PKR) and the inducible nitric oxide 
synthase (iNOS). IRF-1 also influences development and function of NK cells and, in addition, 
IRF-1 overexpression induces IFN-α and IFN-β transcription. These cytokines have stimulatory 
effects on macrophages and T cells (Kroger et al., 2002).  
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IRF-1 can also be activated by type I IFN (IFN-α and IFN-β) and type II IFN (IFN-γ). IRF-1 is 
constitutively localized in the nucleus and the consensus-binding sequence motif has been 
determined to be 5´- AANNGAAA -3´ (the consensus recognition sequence for each IRF) that 
appears within the promoter of several IRF-inducible genes (Kroger et al., 2002; Tamura et al., 
2008).  
 
1.2. RNA polymerase II (RNAPII) transcription cycle  
The carboxyl-terminal domain (CTD) of the largest subunit of the RNAPII is essential for 
transcription, because phosphorylation of the CTD was found to be a key event during messenger 
RNA (mRNA) metabolism. Phosphorylation of the CTD varies during the transcription cycle and 
several kinases that are capable of phosphorylation of the CTD have been discovered. The CTD 
consists of multiple repeats of a seven-amino-acid motif which is in turn made up of tyrosine (Tyr), 
serine (Ser), proline (Pro) and threonine (Thr). These amino acids form the consensus heptapeptide 
Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 (Chapman et al., 2007; Palancade and Bensaude, 2003; Prelich, 
2002). 
The functions of the CTD are quite complex as it is involved in all major steps of mRNA formation, 
including transcription initiation and elongation, capping, splicing, and 3´end processing (Fig. 4). A 
variety of kinases have been identified with phosphorylation activity mainly towards the amino 
acids serine 2 and serine 5 (Chapman et al., 2007; Prelich, 2002). In general, during mRNA 
metabolism, the unphosphorylated CTD interacts with a mediator complex (Med) (Fig. 4a) to form 
a preinitiation complex (Fig. 4b). Phosphorylation of the CTD is required to disrupt these 
interactions at elongation of transcription (Fig. 4d) and to assist the recruitment of pre-mRNA 
modification enzymes (Fig. 4f). Serine 5 is phosphorylated first in the initiation complex (Fig. 4c) 
by the cyclin-dependent kinase (CDK) 7, and serine 2 of the CTD phosphorylation is mediated by 
CDK9 upon entry into elongation (Palancade and Bensaude, 2003). Thus, differential 
phosphorylation of serine 2 and serine 5 at the 5´ and 3´ regions of genes appear to coordinate the 
localization of transcription- and RNA-processing factors to the elongation polymerase complex 
(Chapman et al., 2007).  


























Figure 4:  CTD phosphorylation during the transcription cycle 
(A) Recycling. The RNAPII core enzyme is not phosphorylated on the CTD. It may assemble with co-activators such as 
Med to form a holoenzyme. Premature CTD phosphorylation by CDK8 prevents the assembly of RNAPII on the 
promoter. (B) Preinitiation. The unphosphorylated RNAPII assembles onto the promoter sequences with general 
transcription factors, thus forming a preinititiation complex of transcription. The CTD is phosphorylated on serines at 
position 5 (5P) by the CDK7 subunit of general transcription factor II (TFII) H. (C) Initiation. Transcription begins. The 
phosphorylated CTD recruits the capping enzymes and the nascent transcript is capped at its 5´ end. (D) Elongation. 
Phosphorylation of the CTD on serines at position 2 (2P) by the CDK9 subunit of the positive transcription elongation 
factor b (P-TEFb) is required to elongate transcription. (E) RNA processing and transcription termination. The 
phosphorylated CTD recruits the splicing machinery to remove introns and, finally, recruits the cleavage and 
polyadenylation factors that cleave the transcript and add a polyadenylic tail at its 3´ end. This step signals transcription 
to terminate and RNAPII falls off its DNA template. The resulting mRNA is then exported to the cytoplasm. (F) To be 
recycled for another transcription round, RNAPII is dephosphorylated by the TFIIF-dependent CTD phosphatase 1 
(FCP1) (Modified from Palancade and Bensaude, 2003). 
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1.3. Single nucleotide polymorphisms (SNPs)  
With completion of the Human Genome Project, a large number of subtle variations – 
polymorphisms - have been found (Kim and Misra, 2007). The most common type of genetic 
variations is the single nucleotide polymorphism (SNP) with more than 10 million reported in 
public databases, so far (Kubistova et al., 2009). A SNP is a single variation at a specific location in 
the genome that is by definition found in more than 1% of the population. Typically, genotypes of 
these polymorphisms are biallelic, very rarely tri- or tetraallelic, and the average overall frequency 
of SNPs in the human genome is approximately one per 1,000 bp (Kim and Misra, 2007).  
Within a population, a minor allele frequency (MAF) can be assigned for each SNP as a ratio of 
chromosomes in the population carrying the less common variant to those with the more common 
variant. There are marked differences between human populations in terms of the distribution of 
particular SNP variants, thus an SNP allele that is common in one geographical or ethnic group may 
be rarer in another (Kubistova et al., 2009).  
It was found that SNPs do occur less frequently in coding regions of the genome than in non-coding 
regions. SNPs, when present in regulatory sites of a gene, can affect rates of transcription causing 
changes in the production of encoded proteins or may have consequences for transcript 
splicing/stability, transcription factor binding or the sequence of non-coding RNA. On the other 
hand, SNPs located within coding regions can cause alterations in protein structure or function and 
are thus called non-synonymous. SNPs within a coding region will not necessarily change the 
amino acid sequence of the protein, due to degeneration of the genetic code, so polymorphisms in 
which both forms lead to the same polypeptide sequence are termed synonymous (Kim and Misra, 
2007; Kubistova et al., 2009).  
SNPs that have an effect on gene regulation, e.g. a functional effect on gene expression, are said to 
be regulatory SNPs (rSNPs). The rSNPs are potentially susceptibility SNPs for phenotypes, 
including diseases (Buckland, 2006). Regulation at the level of transcription initiation and RNA 
processing defines downstream biological effects. Such regulation occurs in cis, directly affecting 
the regulated gene, but it can act in trans by altering activity of downstream genes. Significant 
interindividual differences in gene expression patterns are common and may result from both 
environmental factors and cis- or trans-mediated genetic effects (Johnson et al., 2005).  
SNPs in immune response genes (e.g. TLRs, cytokines, or immunoglobulins) may have severe 
consequences, as these immune molecules are implicated in the pathogenesis of a large number of 
human diseases. Thus variations in the DNA sequence of these genes can affect whether or how 
humans develop diseases and respond to pathogens, chemicals or drugs (Kubistova et al., 2009).  
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The most commonly studied polymorphisms, nonsynonymous changes that alter amino acid coding, 
appear in many cases insufficient to account for interindividual differences in disease aetiology and 
response to therapies. Further, it is estimated that functional polymorphisms that are cis-regulatory 
in the human genome outnumber those that alter protein sequence, and that the bulk of regulatory 
polymorphisms remain to be discovered (Johnson et al., 2005). 
 
1.3.1. Methods for investigation of rSNPs 
Investigation of SNPs that might cause changes in cellular biological processes that induce disease 
states is performed in disease genetics studies. A typical approach are case-control association 
studies, where genotyping in a patient group and healthy control population is performed to 
investigate relationships between specific genotypes (SNPs) and phenotypic characteristics (Kim 
and Misra, 2007; Kubistova et al., 2009).    
The reporter gene assay is a widely used and very sensitive method for the study of promoter 
strength. Briefly, the promoter is cloned directly upstream of the reporter gene in a promoterless 
vector and introduced into cultured cells. The reporter gene is expressed in an extra chromosomal 
state and the protein activity can be quantified. Thus, the effect of isolated SNPs can be assayed. 
But, because the promoter is not in its natural chromatin environment and because of the different 
behaviour of cells in culture, the results are sometimes difficult to correlate to in vivo observations 
(Pampin and Rodriguez-Rey, 2007).  
The electrophoretic mobility shift assay (EMSA) is a major method for detecting DNA/protein 
interactions. A labelled double-stranded oligonucleotide is mixed with a nuclear extract prepared 
from cells that express transcription factors. The formation of DNA/protein complexes result in a 
retardation of mobility during electrophoresis and, thus, a separation from the free probe. The effect 
of an rSNP on transcription factor binding results in changes of electrophoretic mobility (Pampin 
and Rodriguez-Rey, 2007). 
Quantification of gene expression is another approach of functional studies to investigate rSNPs. 
These analyses rely on comparisons of the relative abundance of the mRNA between genotypic 
groups (Buckland, 2006).  
To circumvent intrinsic errors in interindividual comparison and to analyse allele-specific gene 
expression within its natural genomic environment, two techniques have been developed more 
recently: allele-specific transcript quantification (ASTQ) and haplotype-specific 
immunoprecipitation (HaploChIP).  
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For the first technique, a polymorphism in the transcribed region of a gene is used as a marker to 
distinguish between the allelic mRNA products of genes harbouring a putative regulatory 
polymorphism within their regulatory regions in one double heterozygous individual. The relative 
abundance of allelic mRNAs from a heterozygous individual is then quantified in allele-specific 
polymerase chain reactions (PCR). Both gene copies originate from the same tissue sample and 
identical environmental influences, so each allele should be equally expressed regardless of the 
absolute level of gene expression. The ratio of the abundance of each allele is therefore expected to 
be ~1. In samples that are heterozygous for a regulatory variant, mRNA originating from one 
chromosome will be expressed at a higher level than that from its sister chromosome and this is 
detected by changes in the ratio of the amount of each mRNA allele (Buckland, 2006).  
The second approach to measure allele-specific transcription in vivo, HaploChIP, investigates 
RNAPII binding to genomic DNA (gDNA) using an SNP in the promoter region as a marker. Here 
an antibody specific to serine 5 phosphorylated (ser5-P) RNAPII is added to fragments of cross-
linked DNA/protein complexes and the immunoprecipitated chromatin is measured for the relative 
amount of each precipitated allele. This method has the advantage of allowing the functional 
association of DNA variants in the promoter with changes in gene expression (Buckland, 2006; 
Knight et al., 2003; Pampin and Rodriguez-Rey, 2007).  
 
1.3.2. Association of the polymorphisms CD14 rs2569190 and IRF-1 rs2549009 with various 
disease conditions 
The CD14 rs2569190 (C/T) polymorphism was first identified by Baldini and colleagues. The 
homozygous TT genotype of this SNP was described as being associated with higher levels of 
sCD14 and decreased IgE levels in children who were skin test-positive for local aeroallergens 
(Baldini et al., 1999). Later, this SNP was found to influence CD14 gene expression via a 
differential effect on binding of transcription factors Sp1, Sp2 and Sp3 to gDNA in different cell 
types (LeVan et al., 2001). Also, a gene-environment interaction between T allele carriers and 
Helicobacter pylori antibodies on serum total IgE was observed in Finish children (Virta et al., 
2008). Further, the homozygous TT genotype was suggested to confer an increased risk of alcoholic 
liver disease progression, especially liver cirrhosis in a Finnish population (Jarvelainen et al., 2001), 
and it was found to be associated with mild cryptogenic chronic liver disease (Von Hahn et al., 
2008). The same genotype was later found to be associated with significantly higher sCD14 levels 
in patients with hepatitis C virus (HCV) infection (Meiler et al., 2005). Another study reported a 
possible relationship between CD14 rs2569190 TT genotype and the formation of portal lymphoid 
aggregates in chronic HCV infection (Askar et al., 2009). 
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The SNP rs2549009 (G/A) is located within the promoter region of the transcription regulator gene 
IRF-1. The homozygous genotype AA was associated with the outcome of HCV genotype 3 
infection (Wietzke-Braun et al., 2006). This genotype was also positively associated with Th1-type 
response in patients with chronic HCV infection, suggesting that this SNP variant might be 
beneficial for viral elimination in chronic HCV and IFN therapy (Saito et al., 2002).  
Additionally, it was shown that DNA constructs, containing the genetic polymorphism rs2549009, 
modified promoter activity in luciferase promoter assays (Saito et al., 2001; Schedel et al., 2008).  
 
1.4. Aims of this work 
The aim of this study is to determine whether the polymorphisms rs2569190, located within the 
CD14 gene, and rs2549009, located within the promoter region of the IRF-1 gene, confer any 
regulatory effect on transcriptional activity in their natural genomic context in human peripheral 
blood mononuclear cells (PBMC). For this purpose the technique HaploChIP, which assesses the 
relative binding frequency of RNAPII to allelic gene promoter regions at different stages of the 
transcription cycle by using RNAPII-specific antibodies, was established and applied. 
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2.1. Blood donors  
For cross-linking of proteins to the DNA in PBMC (during the HaploChIP method see 2.3.) blood 
samples from a cohort of 13 healthy Caucasians (6 female, 7 male; mean age 30.0 years, range 23-
48) were taken. PBMC were prepared by Ficoll density centrifugation and isolated, and cross-linked 
cells were stored at -80°C for further analyses. CD14 rs2569190 and IRF rs2549009 heterozygotes 
(n=9; n=6) were identified (see 2.2.) and asked to give further blood samples of 30 ml venous blood 
for immunoprecipitation during HaploChIP. Experiments were performed at least two times each 
for independent replication. Later, these 13 donors were included in a larger cohort consisting of 42 
healthy Caucasians which was used for further functional and association studies by our research 
team (i.e. IRF-1 gene expression with regard to IRF-1 rs2549009 genotypes). 
 
2.2. Genotyping 
From whole blood samples, gDNA was purified using the QIAamp DNA Blood Mini Kit following 
the blood and body fluid spin protocol (Qiagen, Hilden, Germany). Genotyping was performed 
using 10-40 ng gDNA. Allelic discrimination of variant positions within the CD14, IRF-1 and the 
imprinted small nuclear ribonucleoprotein polypeptide N (SNRPN) gene was achieved by different 
SNP-specific assays (Tab. 1). 
 
Tab. 1: Genotyping of variant positions using different SNP-specific assays 
  gene and SNP # assay type reference 
  CD14 rs2549190 5´-nuclease assay (custom designed) (Maouzi, 2007) 
  CD14 rs5744455 
  CD14 rs2563298 
allele-specific tetra-primer amplification 
refractory mutation system- (ARMS-) PCR  
(Bregadze, 2010; Mertens 
et al., 2009) 
  IRF-1 rs2549009 5´-nuclease assay (custom designed) (Maouzi, 2007) 
  IRF-1 rs2549007 
  IRF-1 rs2706384 
allele-specific primer pairs this thesis 
  SNRPN rs705 
5´-nuclease assay (ABI genotyping assay 
C_2066555_10) (Mertens et al., 2009) 
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2.2.1. Discrimination of variant positions using 5´-nuclease assays 
Genotyping of variant positions by allelic discrimination in 5’-nuclease assays was carried out in 
the sequence detection system ABI StepOnePlus or ABI prism 7000 (Applied Biosystems, 
Darmstadt, Germany) according to supplier’s instructions. For genotyping of CD14 rs2549190 and 
IRF-1 rs2549009, custom designed 5´-nuclease assays were available from an earlier thesis. 
Discrimination of gDNA and transcript variants at SNP rs705 within the imprinted gene SNRPN 
was carried out using a commercially available genotyping assay (Applied Biosystems). 
 
2.2.2. Discrimination of variant positions using ARMS-PCR 
Amplification of ARMS-PCR via tetra-primers was performed using conventional PCR followed by 
analysis of PCR products in agarose gels. This method uses two outer primers and two inner 
primers, which are specific for the variant position of interest. One outer primer and one inner 
primer each are specific for the variant alleles of SNP, while both outer primers together generate a 
non-SNP- but gene-specific PCR product. Thus, it is possible to generate allele-specific as well as 
non-allele-specific amplicons in one reaction. Tetra-primers were designed using a software 
publicly provided by Ye and colleagues (Ye et al., 2001).  
Amplification CD14 rs5744455 was performed using 10-20 ng gDNA in a total of 25 µl GoTaq 
Master Mix (GoTaq Green-/Colorless- Master Mix, Promega GmbH, Mannheim, Germany) with 
0.18 µM primers each (rs574 tetra T f 5´-AAG GAA GGG GGA ATT TTT CTT TAG CCT-3´, 
rs574 tetra C r 5´-GGT AGA ATT AGG TTC AAG AAA AGG AAG GTG-3´, rs574 tetra for 5´-
CTG AGC AAC AGA GCA AGA CTC TAT CTC A-3´and rs574 tetra rev 5´-CAT TTC TTT GAC 
TTC TTC CTT GTC TTG G-3´). Cycling conditions were 3 min initial denaturation at 94° C, 40 
cycles of 1 min denaturation at 94° C and 1 min annealing at 62° C and 1 min elongation at 72° C.  
Genotyping of CD14 rs22563298 was performed similarly with 0.18 µM primers each (rs2563 tetra 
G f 5´-CCC ACC TTT ATT AAA ATC TTA AAG AAC AGG-3´, rs2563 tetra T r 5´-TAA AGG 
TCT GTT AAA TGA ATG ACA CGA AA-3´, rs2563 tetra for 5´-TTT GCC TAA GAT CCA 
AGA CAG AAT AAT G-3´and rs2563 tetra rev 5´-TTT CTT AGG GAG TTA GGA TGA AGA 
AAG C-3´) using identical cycling conditions except annealing at 60° C.  
For CD14 rs5744455 products of 277 bp for the outer primers, 142 bp for the C allele and 192 bp in 
size for the T allele were generated (Fig. 5a). PCR products in size of 247 bp for outer primers, 143 
bp for the G allele and 163 for the T allele were found for genotyping of CD14 rs2563298 (Fig. 5b). 
Thus, product patterns of 277/142, 277/142/192 and 277/192 bp correspond to CC, CT and TT 
genotypes of CD14 rs5744455. ARMS-PCR patterns of 247/143, 247/143/163 and 247/163 bp 
correspond to CD14 rs2563298 GG, GT and TT genotypes (Mertens et al., 2009). 














2.2.3. Discrimination of variant positions using allele-specific primers 
Discrimination of the polymorphisms rs2549007 and rs2706384 within the IRF-1 promoter region 
was achieved on gDNA from the larger cohort of healthy donors in real-time PCR using allele-
specific primers. For genotyping of the variant positions, primers were used that are able to 
distinguish between different alleles of the genetic polymorphisms. Therefore, allele-specific 
primers were designed modelled on tetra-primers, but applicable for real-time PCR (Ye et al., 
2001). Unlike ARMS-PCR, which also generates non-SNP-gene-specific PCR products for outer 
primers in this real-time PCR approach, only allele-specific products originate depending on the 
genotype for the respective donor (Fig. 6).  
IRF-1 rs2549007 genotyping was performed using 2 ng gDNA in a total volume of 10 µl using 0.30 
µM of primers each (IRF-1 rs254 for 5´-AGG CTT TCT GCC TTC TTC ACT T-3´ and IRF-1 
rs254 G r 5´-GTA TAT CTC CCG AAC GCA TGC-3´, or IRF-1 rs254 A r 5´-GGT ATA TCT 
CCC GAA CGC ATG T-3´) in standard SYBR green reactions (Plantinum SYBR GREEN qPCR 
SuperMix-UDG, Invitrogen GmbH, Darmstadt, Germany). Cycling conditions were 2 min initial 
denaturation for activation of the antibody blocked Taq DNA polymerase at 50°C, followed by 2 
min denaturation at 95°C and 45 cycles of 15 s at 95°C denaturation and 30s at 60°C annealing and 
extension. 
Genotyping of IRF-1 rs2706384 was also performed in standard SYBR green (Invitrogen) 
amplification reactions of 4 ng gDNA using 75 nM of primer pairs each (IRF-1 rs270 rev 5´-CTG 
TCC TCT CAC TCC GCC TTG TCC-3´ and IRF-1 rs270 C f 5´-CAA GTG CCC GGG CGA 
CCC-3´, or IRF-1 rs270 A f 5´-CAA GTG CCC GGG CGA CCA-3´). Cycling conditions were 
equal, but an annealing step at 67°C for 30 s was necessary.  
Figure 5: Discrimination of CD14 rs5744455 and CD14 rs2563298 using ARMS-PCR – agarose gel 
For analysis of PCR products for the variant position CD14 rs5744455 (a) and CD14 rs2563298 (b) agarose gels of 2% 
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Specificity of PCR products was validated by melting curve analyses. In addition to the allele-
specific PCR products, non-specific amplicons were also generated to a rather lesser amount (> 19-
fold difference), most probably due to unspecific binding of primers. Thus, the different genotypes 
GG, AG or AA for IRF-1 rs2549007 and CC, AC or AA for IRF-1 rs2706384 were assigned due to 
the very predominant amplification of the one or the other allele or to a rather equal amplification of 























Figure 6: Genotyping of IRF-1 rs2549007 and IRF-1 rs2706384 using allele-specific primers in real time PCR 
Discrimination of variant positions within the promoter region of IRF-1 was achieved in real-time PCRs using allele-
specific primer for (a) IRF-1 rs2549007 and (b) IRF-1 rs2706384. In general, allele-specific primers generated PCR 
products with fluorescence signals of different intensities representing specific and unspecific binding of primers, 
depending on the respective genotype. Genotypes GG, AG or AA for IRF-1 rs2549007 (a) and CC, AC or AA for IRF-
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2.3. HaploChIP 
HaploChIP analysis comprised (a) cross-linking of proteins to the DNA and enzymatic shearing of 
chromatin, (b) an immunoprecipitation of chromatin fragments by antibodies with different 
specificities, and (c) a restriction endonuclease digestion of amplified chromatin fraction. 
 
2.3.1. Cross-linking and enzymatic shearing of chromatin 
Chromatin immunoprecipitation was conducted using the ChIP-IT Express kit (Active Motif, 
Rixensart, Belgium) according to the supplier’s protocol. In brief, 1-10x106 freshly isolated PBMC 
were cross-linked using 1% formaldehyde for 5-6 min (Fig. 7a). After isolation of nuclei (Fig. 7b) 
enzymatic digestion reactions were performed using a shearing cocktail for about 8-10 min at 37°C 
(Fig 7c). Sheared chromatin was then stored in aliquots at -80°C until further use for 
immunoprecipitation or as control ‘input’ DNA.  
 
2.3.2. Immunoprecipitation  
Sheared chromatin corresponding to 1x106 cells was subjected to immunoprecipitation by 4 µg of 
an (i) IgG-antibody directed against the transcriptionally inactive, ser5-P RNAPII (39097 clone 
4H8, Active Motif) or by a control mock antibody (53010 negative control mouse IgG 101226, 
Active Motif) (Fig. 7d). Antibody-bound protein/DNA complexes were captured through use of 
magnetic protein G-coated beads.  
(ii) Immunoprecipitation was also performed by IgM-antibodies directed against ser5-P (MMS-
134R clone H14, Covance, California, USA) or the transcriptionally active, serine 2 phosphorylated 
(ser2-P ) RNAPII (MMS-129R clone H5, Covance) or by an IgM-isotype (ITC0692 clone A16G8, 
Linaris GmbH, Wertheim-Bettingen, Germany) using 5 ng of an bridging anti-mouse-IgM antibody 
(315-005-020, Jackson ImmunoResearch, West Grove, Pennsylvania, USA) (Fig. 7d). The 
additional bridging step was necessary to allow immunoprecipitations by IgM antibodies and 
magnetic beads, which are specific for IgG antibodies because of its protein G coat. Bridging was 
performed by pre-treatment of 25 µl protein G magnetic beads with 5 µg of the anti-IgM antibody 
for 1 h at 4° C according to supplier’s instructions.  
Captured chromatin was then subjected to reverse-cross-linking and protease K digestion (Fig. 7e). 
 









2.3.3. Restriction fragment length polymorphism (RFLP) analysis 
RFLP analysis included amplification of regions around CD14 rs2569190 or IRF-1 rs2549009, 
followed by SNP-dependent digestion. Non- and precipitated chromatin fragments (Fig. 7e) were 
used as templates for low cycle number or standard cycle number PCR reactions spanning CD14 
rs2569190 or IRF-1 rs2549009. PCR products were then subjected to digest reactions using 
respective SNP-specific endonucleases.  
 
2.3.3.1. Amplification of purified chromatin fragments 
Amplification spanning a region of 201bp around CD14 rs2569190 was performed using 8 µl 
captured and 0.8 µl non-captured material in a total of 100 µl GoTaq Master Mix (Promega GmbH) 
with 0.30 µM primers each (rs2569190 for 5´-GAC ACA GAA CCC TAG ATG CCC T-3´and 
rs2569190 rev 5´-GTG AAC TCT TCG GCT GCC TC-3´). Cycling conditions for (i) low cycle 
number PCR were 2 min initial denaturation at 94° C, 24-28 cycles of 30 s denaturation at 94° C 
and 1 min annealing and elongation at 60° C, followed by a final elongation step for 7 min at 60° C. 
(ii) Standard cycle number PCRs (40-45 cycles) were run under the same conditions.  
Amplification spanning IRF-1 rs2549009 (142bp) was performed using 4 µl antibody-captured and 
0.4 µl non-immunoprecipitated material in a total of 50 µl GoTaq Master Mix (Promega GmbH) 
with 0.30 µM of primers each (IRF rs2549 for 5´-CAG GAG GGT GAA AAG ATG GCC-3´and 
IRF rs2549 rev 5´-CGA GCG CTC CCA ATC CAC-3´). Cycling conditions were 3 min initial 
denaturation at 94° C, 45 cycles of denaturation at 94° C for 30 s, annealing for 30 s at 60° C and 





b c d e a 
Figure 7: Schematic overview of the HaploChIP technique 
The principle procedure of the HaploChIP technique taken from Version G (modified) of ChIP-ITTM Instruction Manual 
(Active Motif) is shown. After cross-linking of proteins to the DNA (a), isolated chromatin (b) was subjected to 
enzymatic shearing (c). Sheared chromatin fragments were than immunoprecipitated by different antibodies (d) and 
subjected to reverse-cross-linking and digestion with protease K (e). 
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Size of PCR products was determined in 1% agarose gels. Because of unspecific products, all PCR 
reactions were purified and concentrated by gel extraction using the PrepEase gel extraction kit 
(USB, Cleveland, OH, USA) according to supplier’s instructions.  
 
2.3.3.2. Restriction endonuclease digestion of amplicons  
SNP-specific endonucleases were used for allelic digestion of PCR products. Therefore, detection 
of highly specific enzymes was achieved using the software NEBcutter V2.0 (Vincze et al., 2003).  
For allelic digestion of CD14 PCR products, a region of 41 nt around CD14 rs2569190, 20 nt 
upstream and downstream, was analyzed for C allele- (Fig 8a) and T allele- (Fig 8b) specific 
endonucleases. The enzyme HaeIII was found to recognize a DNA sequence containing CD14 
rs2569190 C, while HpyCH4III (TaaI) was found to recognize a DNA sequence containing the T 
allele. 
Identification of suitable endonucleases for IRF-1 rs2549009 was performed similarly. Amongst 
others, the enzymes NciI (BcnI) and BstNI (MvaI) were indicated by the software (Fig 9) to be 
specific for a DNA sequence containing the IRF-1 rs2549009 wild-type allele G or variant allele A 





















Figure 8: Detection of CD14 rs2569190 C 
and T allele-specific endonucleases using 
the NEBcutter V2.0 
A region of 20 nt in both directions, upstream 
and downstream, of CD14 rs2549190 was 
analyzed for allele-specific endonucleases 
using the software NEBcutter V2.0. All 
commercially available endonucleases 
specific for the shown sequence are indicated. 
DNA sequences containing (a) the wild-type 
allele C and (b) the variant T, located at 
position 21 in the cut-out, are recognized by, 
amongst others, HaeIII and HpyCH4III 
(TaaI). 





























Digestion of CD14 rs2569190 was carried out in a total of 10 µl digestion reactions using 8 µl 
purified PCR product with 5 U endonucleases, HaeIII or TaaI (Fermentas GmbH, St. Leon-Rot, 
Germany) in respective buffers at 37° C or 65° C for at least for 4 h or overnight.  
Digestion of IRF-1 rs2549009 was performed similarly, using 5 U endonucleases, BcnI or MvaI 
(Fermentas GmbH) in a total of 10 µl and respective buffers at 37° C for 2-3 h. 
All digestion reactions were stopped and purified again using the PrepEase gel extraction kit (USB) 
following the PCR purification protocol. For digestion fragments see Fig. 10. 
a
b
Figure 9: Detection of IRF-1 rs2549009 
G and A allele-specific endonucleases 
using the NEBcutter V2.0 
A DNA sequence region of 20 nt upstream 
and downstream of IRF-1 rs2549009 was 
analyzed for allele-specific endonucleases 
using the software NEBcutter V2.0. All 
commercially available endonucleases 
specific for the shown sequence are given. 
DNA sequences containing (a) the wild-
type allele G or (b) the variant allele A, 
located at position 21 in the cut-out, are 
recognized by NciI (BcnI) or BstNI (MvaI). 
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Because of an excess of PCR products during the saturation stage of the amplification reaction, 
allelic amplicons might bind to each other independently of the single variant position during 
annealing, thus forming hybrids composed of one strand containing one allele and a complementary 
strand carrying complementary nucleotides of the other allele. Theoretically, up to 50% of 
amplicons might be hybrids. These hybrids could not be recognized and digested by the allele-
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Figure 10: Digestion fragments 
(a) Digestion of CD14 rs2569190 PCR 
with HaeIII or TaaI resulted in specific 
digestion fragments for each reaction. (b) 
Digestion of IRF-1 rs2549009 PCR with 
BcnI or MvaI also resulted in different 
fragments of specific size for each variant 
allele. During PCR, hybrid (H) products 
were also found to be generated in 
addition to completely homologous 
double-stranded amplicons. In addition to 
the respective SNP-specific recognition 
sequence, SNP-independent DNA 
sequences within the amplicons were also 
digested by the restriction enzymes. The 
relative amount of digested and 
undigested fragments was then analyzed 
in a bioanalyzer. 
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2.3.3.3. Quantification of DNA fragments with a bioanalyzer 
All digested fragments were analyzed in the Agilent 2100 bioanalyzer using the DNA 1000 
LabChip kit (Agilent Technologies, Böblingen, Germany) according to the supplier’s instructions. 
The bioanalyzer uses a chip-based technology to separate and quantify nucleic acids. DNA 
fragments are separated according to their length in a gel within the chip and because of different 
fluorescence intensities, the software is able to calculate respective molarities for each fragment.  
1 µl of each cleaned digestion reaction, CD14 rs2569190/HaeIII or TaaI (Fig. 11a) or IRF-1 
rs2549190/BcnI or MvaI (Fig. 11b), was analyzed for the amount of digested and undigested PCR 
fragments. The relative amount of the respective variant allele fragments was calculated by given 
molarities for each fragment and PCR hybrid. 
 























Calculation example for RFLP of CD14 rs2569190: 
With the given molarities for each digestion fragment, the ratio of CD14 rs2569190 promoter 
variants was calculated. C = CD14 rs2569190 C allele PCR fragments, T = CD14 rs2569190 T 
allele PCR fragments, H = hybrid of CD14 rs2569190 C and T allele PCR fragments 
 
Digestion with HaeIII:  (T + H) : C = 96.2 : 13.4 = 7.18 
Digestion with TaaI:    T : (H + C)= 42.1 : 31.9 = 1.32 
     T = 100% - C - H 
     T = 56.90%  C = 12.22%  H = 30.88% 
     T = (56.90% · 2 + 30.88%) : 2 = 72.34% 
     C = (12.22% · 2 + 30.88%) : 2 = 27.66%  
     ratio of CD14 rs2569190 T/C promoter variants = 2.61 
Figure 11a: CD14 rs2569190 RFLP 
analysis of output material from individual 
#3 using the Agilent 2100 bioanalyzer 
Output material (individual #3), was 
subjected to amplification spanning a region 
around CD14 rs2569190 SNP and yielding a 
product of 201bp in size. Amplicons were 
subjected to two different restriction enzyme 
digestions with TaaI and HaeIII. Digestion 
with TaaI (indicated in red) resulted in 
fragments of 135bp, 42bp and 24bp in size 
representing T allele DNA, while fragments 
of 177bp and 24bp represent C allele DNA. 
Digestion with HaeIII (indicated in blue) 
resulted in the undigested amplicon of 201bp 
in size for the T allele, while fragments of 
152bp and 49bp represent C allele DNA. 
Restriction digest analyses were carried out 
in a bioanalyzer. Ratios of T and C alleles 
were calculated from the molar quantities 
given for the respective fragments greater 
than 50 bp according to suppliers´ instruction 




























































































































Calculation example for RFLP of IRF-1 rs2549009: 
With the given molarities for each digestion fragment, the ratio of IRF-1 rs2549009 promoter 
variants was calculated. G = IRF-1 rs2549009 G allele PCR fragments, A = IRF-1 rs2549009 G 
allele PCR fragments, H = hybrid of IRF-1 rs2549009 G and A allele PCR fragments 
 
Digestion with MvaI:  (G + H) : A = 86.8 : 28.8 = 3.01 
Digestion with BcnI:    G : (H + A)= 41.8 : 74.8 = 0.56 
     G = 100% - A - H 
     A = 24.9%  G = 35.9%  H = 39.2% 
     A = (24.9% · 2 + 39.2%) : 2 = 45.5% 
     G = (35.9% · 2 + 39.2%) : 2 = 55.5%  
     ratio of IRF-1 rs2549009 A/G promoter variants = 0.82
Figure 11b: Analysis of RFLP with the 
Agilent 2100 bioanalyzer using the example 
of H5 antibody captured HaploChIP 
material of individual #1 
HaploChIP material (individual #1), was 
subjected to amplification spanning a region 
around IRF-1 rs2549009 SNP and yielding a 
product of 142bp in size. Amplicons were 
subjected to two different restriction enzyme 
digestions with MvaI and BcnI. Digestion 
with MvaI (indicated in red) resulted in 
fragments of 69bp, 49bp and 24bp in size, 
representing A allele DNA, while fragments 
of 118bp and 24bp represent G allele DNA. 
Digestion with BcnI (indicated in blue) 
resulted in fragments of 91bp, 36bp and 
15bp in size representing A allele DNA, 
while fragments of 72bp, 36bp, 19bp and 
15bp represent G allele DNA. Restriction 
digest analyses were carried out in a 
bioanalyzer. Ratios of A and G alleles were 
calculated from the molar quantities given 
for the respective fragments greater than 50 
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2.4. Sequencing of the CD14 gene  
First, three overlapping regions of the CD14 gene and nearby regions spanning 2,101 nucleotides 
(publication 6.1./Fig. 1) were amplified using two mixtures of 25ng gDNA from 5 different 
individuals (5ng gDNA per donor) each, heterozygous at CD14 rs2569190, as templates and 0.36 
µM of sequencing primers each (see Fig. 18 and 5.3.). Secondly, the first overlapping region (761 
nt) was amplified separately for each of the 10 individuals using 60ng gDNA and sequencing 
primer pair 1 (5.3.). All products were purified following the spin protocol of the QIAquick PCR 
Purification Kit (Qiagen) and sequenced by SeqLab (SeqLab, Göttingen, Germany) using an 
automated sequencer. Alignments and analyses were performed using the BLAST program of 
NCBI (National Institutes of Health, Bethesda, Md, USA) and version 2.01 of the software 
Chromas LITE (Technelysium Pty Ltd, Tewantin, QLD, Australia). 
 
2.5. ASTQ 
The functional impact of the CD14 and IRF-1 promoter SNPs were investigated in several in vivo 
studies. In addition to HaploChIP analyses, used to investigate the functional relevance of SNPs on 
promoter activity, the impact of the respective SNPs was determined by ASTQ. The ASTQ 
technique requires an additional SNP within the transcript as a marker to distinguish transcripts 
originating from the respective promoter variant. ASTQ of the CD14 and IRF-1 gene was 
performed in parallel within our research team as part of several medical theses (Aidery, 2010; 
Bregadze, 2010; Mansur, 2008). 
 
2.6. Haplotyping 
To relate HaploChIP results to those obtained by ASTQ, it was necessary to assign allelic 
transcripts to respective promoter variants. Therefore, haplotyping of different SNPs within the 
CD14 and IRF-1 gene was carried out on gDNA from individuals heterozygous in both the 
promoter variant and the ASTQ marker SNP.  
Additionally, other genetic variants within the CD14 and IRF-1 gene were also investigated for 
their linking to respective promoter polymorphisms.  
 
2.6.1. Haplotyping of polymorphisms within the CD14 gene 
Haplotyping of 4 genetic polymorphisms within the CD14 gene (rs5744455, rs2569190, rs4914, 
rs2563298) was performed on gDNA of the larger cohort using different geno-/haplotyping 
experiments.  
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In brief, allele-specific primers for CD14 rs5744455 or CD14 rs2569190 were used to generate 
amplicons of about 2,000 nt in size, spanning all the variant positions of interest. The CD14 
rs5744455 or CD14 rs2569190 allelic PCR products were used as templates for distinguishing of 
the remaining polymorphic positions in different genotyping assays (see 2.2.). Haplotyping was 
performed in a collaborative approach and also became part of a medical thesis (Bregadze, 2010; 
Mertens et al., 2009).      
 
2.6.2. Haplotyping of polymorphisms within the IRF-1 gene 
In genotyping experiments of the IRF-1 genetic variants rs2549009, rs2549007, rs2706384 and 
rs839, a correlation between IRF-1 rs2549009 genotypes and genotypes of the other genetic 
variants was observed. Thus, it was possible to assess haplotyping of these polymorphisms 
statistically, without further experiments. Therefore, linkage disequilibrium (LD) of haplotypes 
IRF-1 rs2549009 and rs839 or rs2549007 or rs2706384 was calculated using the software 
HaploView version 4.1 and expressed as D´ and r2 (Barrett et al., 2005). Unlike D´, which 
represents the difference between the observed and expected frequencies of haplotypes for two 
biallelic loci, r2 indicates the negative relation between LD and the physical distance of sites. Both 
only have a maximum of 1 if the two loci have the same allele frequencies and if there is a positive 
association between the most common alleles at the two loci (Awadalla et al., 1999; Hedrick and 
Kumar, 2001; Lazarus et al., 2002).  
 
2.7. Statistical analyses 
Correlation and linear regression analyses were performed using the software GraphPad Prism 
version 4.00 (GraphPad Software Inc, La Jolla, California, USA). P-values < 0.05 were considered 
significant. Total IRF-1 gene expression analysis with regard to IRF-1 rs2549009 promoter 
genotypes was determined using one-way ANOVA (Kruskal-Wallis test) also by applying the 
software GraphPad Prism version 4.00 (GraphPad Software). Exact test for Hardy-Weinberg 
equilibrium (HWE) and LD (D´and r2) were assessed by HaploView version 4.1 (Barrett et al., 
2005). HWE is a parameter for the genotypic frequency of two alleles of one gene locus.  
Calculated on the basis that the alleles A and a have the frequencies p and q (=1-p), the equilibrium 
genotypic frequencies are AA=p2, Aa=2pq and aa=q2 (Mayo, 2008).  
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3. Results & Discussion 
 
3.1. Establishing and applying HaploChIP to assess the transcriptional activity at CD14 
rs2569190 promoter variants in a natural genomic context 
Genetic variations within the TLR4 gene have been associated to individual endotoxin sensitivity 
(Arbour et al., 2000; El-Omar et al., 2008). It is also suggested that genetic polymorphisms within 
the CD14 gene, in particular CD14 rs2569190 SNP, do determine the outcome of LPS exposure 
(Baldini et al., 1999; Campos et al., 2005; Levan et al., 2008; Meiler et al., 2005; Virta et al., 2008). 
Thus, to address the question whether CD14 rs2569190 (C/T) has any functional impact on CD14 
promoter activity, HaploChIP analyses using antibodies directed against ser5-P or ser2-P isoforms 
of the RNAPII were conducted on ex vivo-derived PBMC from healthy Caucasians.  
Therefore, 13 healthy Caucasian blood donors were first of all genotyped at this variant position 
and the CD14 rs2569190 heterozygotes (n=9) were used for the investigation of the CD14 promoter 
activity. Genotype distribution was found to be in line with HWE (Tab. 2). Eleven of the 13 blood 
donors became part of a larger cohort consisting of altogether 42 healthy Caucasians used for 











According to public databases (NCBI) two different transcript variants of the human CD14 gene 
exist (Fig. 12). The variant position CD14 rs2569190 which was formerly supposed to be located 
within the promoter region (at position -159 from transcription start point), is now assumed either to 
be located within the coding region (transcript variant 1: NM_000591.2) or within intron 1 
(transcript variant 2: NM_001040021.1). In experiments designed to determine the splice variant 
expressed in PBMC, transcript variant 2 was found to be the predominant splice variant, meaning 
that in PBMC CD14 rs2569190 is located within intron 1 of the CD14 gene (Bregadze, 2010; 
Mertens et al., 2009).  
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Figure 12: Schematic overview of the organization of the CD14 gene and transcript variant 
(a) The CD14 gene is located on chromosome 5. The gene and the nearby 5’ and 3’ regions contain four SNPs with 
MAFs > 0.1 as indicated in blue. Presence of these four SNPs was confirmed by sequencing the indicated region. (b) 
According to public database NCBI, two different transcript variants exist. In transcript variant 1, CD14 rs2569190 is 
located within the 5’ untranslated region (UTR) and because of its intronic location in variant 2, CD14 rs2569190 is 
absent from transcript variant 2 (Modified from Mertens et al., 2009). 
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3.1.1. CD14 rs2569190 RFLP analyses with low cycle number PCR 
To establish the HaploChIP technique, formalin-fixed and enzymatically sheared chromatin from 
heterozygous donors was immunoprecipitated by an IgG antibody specific for ser5-P RNAPII. This 
specifically captured material was subjected to RFLP analysis; including amplification of the 
immunoprecipitated material, digestion of PCR products with a SNP-specific endonuclease and 
analysis of digested fragments with a bioanalyzer (see 2.3.3.).  
As a measure to avoid the generation of hybrids, low cycle number PCRs with 24-28 cycles were 
carried out (see 2.3.3.2.). PCR reactions spanning a region around CD14 rs2569190 was performed 
using antibody-captured material (output). As a control for specific immunoprecipitation, non-
captured material (input) was also used as a PCR template. The software NEBcutter V2.0 was used 
to find a SNP-specific endonuclease that is able to distinguish between the CD14 rs2569190 variant 
alleles. The enzymes HaeIII and TaaI were found to be SNP-specific for the CD14 rs2569190 
promoter variants. The first enzyme recognizes and digests a DNA sequence containing the C allele, 
while the second enzyme is specific for a DNA sequence containing the T allele (see 2.3.3.2.). After 
digestion of PCR products (201bp) with the C allele-specific endonuclease, the amount of digested 
(CD14 rs2569190 C promoter variant) and undigested PCR products (CD14 rs2569190 T promoter 
variant) was determined with a bioanalyzer (Fig. 13). Ratios of T and C allele fragments were 
assessed by quantification of molarities for each fragment given by the 2100 bioanalyzer software.  
Additionally, as controls for complete and accurate digestion, RFLP analyses were also performed 
using gDNA from individuals homozygous for the wild-type or variant CD14 rs2569190 alleles. 
Expectedly, only material derived from CC homozygous individuals showed digested fragments of 
expected size (152bp and 49bp), while material from TT homozygotes exhibited only undigested 
PCR products in all samples tested. Input material was found to contain nearly the same amount of 
C and T promoter variants (T/C ratios 1.09 ± 0.05 - 1.13 ± 0.03). Output material, in contrast, 
exhibited a higher amount of CD14 rs2569190 T promoter variants (T/C ratios 1.91 ± 0.19 - 2.87 ± 
0.04) in all 5 heterozygous donors` samples tested (Mertens et al., 2009).  
These findings showed a preferential recruitment of the transcriptionally inactive RNAPII to the 
CD14 rs2569190 T allele captured by an IgG antibody specific for the ser5-P RNAPII. Thus, this 
data provides first evidence for a preferential transcription initiation of the variant CD14 rs2569190 
allele in ex vivo-derived PBMC from healthy Caucasians. 



























Figure 13: Analysis of the CD14 rs2569190 promoter activity in 5 healthy Caucasian blood donors with HaploChIP 
(a) Chromatin from 5 healthy blood donors was immunoprecipitated with an antibody specific for ser5-P RNAPII. 
Specifically captured and non-captured chromatin was subjected to RFLP analysis, including low cycle number PCRs 
and digestion reactions with HaeIII (specific for the CD14 rs2569190 C allele). Materials from digestion reactions were 
analysed with the 2100 bioanalyzer and T/C ratios were calculated by given molarities for each fragment. Material from 
homozygous donors (CC and TT) is shown as controls for complete and specific enzymatic activity (Mertens et al., 
2009). (b) Experiments were performed twice each, and mean ratios and standard deviations are given for HaploChIP 

































































































1.91 2.87 2.12 2.57
0.19 0.04 0.12 0.04













mean 1.09 1.12 1.10 1.13
+/- std. deviation 0.05 0.01 0.05 0.03
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As a control, low cycle number PCR RFLP analysis was also performed with the enzyme TaaI 
specific for the T allele in CD14 rs2569190: PCR material from two individuals (#2 and #4) 
heterozygous in CD14 rs2569190 was subjected to TaaI digestion reaction. Analysis for the amount 
of digested fragments with the 2100 bioanalyzer revealed comparable results: more CD14 
rs2569190 T promoter fragments in output material (T/C ratio 2.54; 2.67), while input control 
showed T/C ratios of ~ 1 (T/C ratio 0.96; 1.06). Controls for accurate enzymatic digestion showed 
the expected fragments (135bp, 42bp and 24bp) in material from an individual homozygous for the 
variant T allele in CD14 rs2569190, as well as material from a CC homozygote, which was digested 
into fragments of the expected 177bp and 24bp (Fig. 14). 
Thus, with this additional experiment it was shown first, that RFLP analysis was performed with 
highly SNP-specific endonucleases and second, that PCR products (input and output material) 













Because of the continued reproducible results and the expected T/C ratios ~1 for input controls as 
well as the highly SNP-specific endonucleases the HaploChIP method was found to generate 
reliable results. But amplification of non- and immunoprecipitated material running low cycle 
number PCR was proved to be difficult. To avoid the development of hybrids it was necessary to 
stop PCR within the linear stage of amplification. Therefore, to spot the sufficient cycle numbers of 
the linear stage, real-time PCRs with input and output material were performed before RFLP. 
However, because of the different cycling conditions of the different PCR forms, it was not always 
possible to determine the sufficient cycling numbers.  
 
 
Figure 14: Analysis of HaploChIP material 
from two individuals (#2 and #4) with RFLP 
using TaaI 
Products of low cycle number PCRs from 
individual #2 and #4 that were also used for 
digestion with HaeIII (Fig. 13) were 
additionally subjected to digestion reactions 
with TaaI. As controls for accurate enzymatic 
activity material from homozygous donors (CC 
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Thus, analysis of CD14 promoter activity by HaploChIP was conducted on material from 5 donors 
who were heterozygous in CD14 rs2569190 only. 
To obtain reliable results also with conventional PCR, an RFLP approach using two different 
digestion reactions at a time in combination with a respective calculation was tried. 
 
3.1.2. CD14 rs2569190 RFLP analyses with standard cycle number PCR 
Amplicons derived from output material subjected to PCRs of 40-45 cycles were digested by two 
different SNP-specific enzymes specific for the wild-type allele (HaeIII) or the variant allele (TaaI) 
in CD14 rs2569190. Digested fragments were analysed again in the 2100 bioanalyzer. By also 
taking the generation of hybrids into account, which were assumed to be neither digested by one or 
the other endonuclease, T/C ratios were calculated (for calculation example see 2.3.3.3.).  
As HaploChIP analyses with low cycle number PCRs, output material was found to contain more 
fragments from the CD14 rs2569190 T variant (T/C ratios 1.44 ± 0.03 - 2.70 ± 0.18) in all 9 
heterozygous donors (Fig. 15). Again, controls for specific enzymatic activity showed fragments of 
expected size. CC homozygous material was digested by HaeIII and resulted in fragments of 152bp 
and 49bp in size, while material from TT homozygotes were left undigested in sizes of 201bp. 
Digestion reaction with TaaI resulted in fragments of 135bp, 42bp and 24bp in size for TT 
homozygotes and fragments of 177bp and 24bp in size for CC homozygous donors (see 2.3.3.2.).  




































Figure 15: Analysis of the CD14 rs2569190 promoter activity in 9 healthy Caucasian blood donors with HaploChIP 
(a) Immunoprecipitated material from 9 heterozygous individuals was subjected to RFLP; including standard cycle 
number PCR (40-45 cycles) followed by digestion reactions of PCR products with SNP-specific enzymes. Digestion 
with HaeIII, which is specific for the C allele in CD14 rs2569190, is indicated in blue. Digestion with TaaI (given in 
red) is specific for the CD14 rs2569190 T variant (Fragments sizes see 2.3.3.3.). Material from digestion reactions were 
analysed with the 2100 bioanalyzer. T/C ratios were calculated by given molarities for each fragment and by taking 
hybrids into account. As controls for correct enzymatic activity, gDNA from homozygous (CC and TT) individuals was 
additionally subjected to RFLP analysis. (b) Experiments were performed twice each and mean ratios and standard 
deviations are given.  
 
b
mean 1.84 1.93 2.50 2.70 2.06
+/- std. deviation 0.03 0.02 0.11 0.18 0.27
experiments n=2 n=2 n=2 n=2 n=2 
1.71 1.91 1.96
0.06 0.03 0.15
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RFLP analysis, running PCRs with standard cycle numbers followed by digestion reactions with 
two different SNP-specific enzymes generated reproducible results similar to those achieved with 
low cycle number PCRs.  
These results indicate again a preferential recruitment of the transcriptionally inactive RNAPII to 
the CD14 rs2569190 T allele in PBMC from healthy Caucasians.  
These data on CD14 rs2569190 promoter activity achieved with HaploChIP are in line with in vitro 
experiments suggesting that a DNA element containing the T allele of CD14 rs2569190 favours 
transcription factor Sp1 and Sp2 binding and therefore promotes gene transcription - at least if the 
promoter variant is located within a plasmid, i.e. in a non-genomic environment (Baldini et al., 
1999; LeVan et al., 2001). 
 
3.1.3. Additional control – immunoprecipitation by a mock isotype (IgG) antibody 
Further, to exclude unspecific antibody binding to ser5-P RNAPII, chromatin from 3 heterozygous 
individuals was additionally immunoprecipitated by a mock isotype (IgG) antibody that should not 
recognize any human epitope specifically. Input, output and mock-captured material was again 
analysed via RFLP running standard cycle number PCRs (40-45 cycles), followed by digestion 
reactions with HaeIII and TaaI. Digested fragments were analysed again with the 2100 bioanalyzer 
and T/C ratios were calculated by given molarities for digested and undigested fragments. As 
expected, input and mock controls showed nearly equal amounts of CD14 rs2569190 T and C allele 
variant fragments (T/C ratios 1.02-1.21) and output material was found again to exhibit more CD14 
rs2569190 T allele fragments (T/C ratios 1.65-1.90). Here as well, controls for correct enzymatic 
activity were found to contain only fragments of expected size (Mertens et al., 2009). Experiments 
were repeated later for two individuals and revealed similar results (Fig. 16). 
























By additional immunoprecipitation with a mock isotype antibody, it was shown that output material 
was specifically captured (by an anti-ser5-P RNAPII antibody). These results of control materials 
confirm the assumption that the HaploChIP technique is a reliable tool for investigation of the 
activity of different CD14 promoter variants by assessing allelic transcription initiation.  
Figure 16: HaploChIP analysis with a mock isotype (IgG) antibody – control for antibody specificity 
(a) Chromatin from 3 different individuals heterozygous in CD14 rs2569190 was additionally immunoprecipitated by a 
mock isotype (IgG) antibody. After amplification of non- and immunoprecipitated materials (input, output and mock 
control) and digestion reactions with HaeIII (indicated in blue) and TaaI (indicated in red) digested fragments were 
analysed in the 2100 bioanalyzer (for fragment size see 2.3.3.2.). Ratios of CD14 rs2569190 T and C gene variants 
were calculated by taking the generation of hybrids into account. As controls for correct enzymatic activity, material 
from homozygous donors (CC and TT) were also subjected to RFLP analysis. (b) Experiments were performed up to 
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3.1.4. Lack of correlation between CD14 rs2569190 promoter activity and allelic CD14 
transcription in PBMC 
Investigations of the CD14 rs2569190 promoter activity with the HaploChIP technique (both with 
low and standard cycle number PCRs) showed a preferential binding of the ser5-P RNAPII to the T 
allele of CD14 rs2569190 in PBMC from healthy individuals. Thus, it was expected that more 
CD14 transcripts would be found derived from the CD14 rs2569190 T allele than from the wild-
type allele in PBMC. 
Allele-specific CD14 transcription was analysed using the SNP rs4914 which is located within the 
CD14 transcript as a marker to distinguish CD14 transcripts derived from different promoter 
variants (Fig. 12). ASTQ was thus applied to material from individuals heterozygous both in CD14 
rs2569190 and in CD14 rs4914. To assign allelic CD14 rs4914 transcripts to respective CD14 
rs2569190 promoter variants, haplotyping was performed (see publication 6.1). However, no excess 
of allelic CD14 transcripts was detected in PBMC from 7 double-heterozygous (CD14 rs2569190 
and CD14 rs4914) donors (Bregadze, 2010; Mertens et al., 2009) (donors #6 and #7 were used for 
both analyses, HaploChIP and ASTQ). 
To address the question of whether another SNP than CD14 rs2569190 might influence CD14 
transcription, genotyping of variant positions within the 5´ and 3´ region of the CD14 gene with 
MAFs >0.1 (rs5744455 - rs2569190 - rs4914 - rs2563298) as well as geno-/haplotyping were 
performed using a combination of ARMS-PCR and genotyping assays (Fig. 12) in collaboration in 
our research team on material from a total of 42 healthy Caucasians (see publication 6.1).  
Genotype distribution of these 4 SNPs was found to be in line with HWE and MAFs (0.26 - 0.44 - 
0.15 - 0.27) were found to be similar to published MAFs for Caucasians at NCBI (0.30 - 0.47 - 0.17 
- 0.21). Additionally, total CD14 transcripts were found to be neither related to genotypes of the 
four variant positions of interest nor to C-T-C-G haplotype (the only one carrying the T allele of 
CD14 rs2569190) or non-C-T-C-G haplotypes in PBMC (Bregadze, 2010; Mertens et al., 2009). 
Taken together, no correlation between allele-specific CD14 promoter activity and gene 
transcription was found in PBMC of healthy Caucasians. 
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3.1.5. Validation of HaploChIP and ASTQ results using the imprinted gene SNRPN 
Because of a lack of correlation between CD14 rs2569190 promoter activity and allele-specific 
transcripts or CD14 transcription rate, control experiments for both methods - HaploChIP and 
ASTQ - were performed. Therefore, input and output material as well as genomic and 
complementary DNA (cDNA) were genotyped at the SNP SNRPN rs705 (G/A) within the 
transcript of the imprinted gene SNRPN. Control experiments were carried out in real-time PCRs 
using allele-specific probes for discrimination of the SNRPN rs705 variant alleles. While G and A 
variants were expected to be found in input and gDNA, output material and cDNA were expected to 
contain only one SNRPN rs705 variant because of monoallelic expression of the imprinted gene. 
For validation of HaploChIP results, non- and immunoprecipitated material from 10 blood donors 
was available. In the input material, one donor was found to be homozygous for the SNRPN rs705 
wild-type allele G, while 4 individuals were found to be homozygous for the variant allele A and 5 
donors were found to carry both variant alleles. All SNRPN rs705 heterozygotes were found to 
exhibit only the G or the A allele in output material, indicating a selective binding of the RNAPII to 
only one variant allele of SNRPN rs705, as expected for monoallelic expression (Fig. 17a). 
Validation of ASTQ experiments was conducted on material from 42 blood donors. In gDNA, 8 
blood donors exhibited the SNRPN rs705 homozygous GG genotype, while 17 individuals each 
were found to carry only the allele A or both variant alleles. As expected, all SNRPN rs705 
heterozygotes who carried both variant alleles in gDNA, showed only the G or the A allele 
expressed in cDNA, indicating here as well monoallelic expression of the imprinted gene SNRPN 
(Mertens et al., 2009). 
Additionally, all individuals (#a - #e) found to be heterozygous at SNRPN rs705 in input material 
contained not only one, but also the same variant allele in output material and in mature mRNA 
transcripts as well (Fig. 17b). Hence selective binding of the ser5-P RNAPII to only one variant 
allele of SNRPN rs705 seems to result in monoallelic expression of the preferred allele, as 
expected. 





















With the expected monoallelic expression of the imprinted gene SNRPN in both output and cDNA, 
results from HaploChIP and ASTQ experiments could be confirmed. Thus, the non-consistent 
HaploChIP and ASTQ results might be due to the impact of a yet - undetected polymorphism or 





Figure 17: Validation of HaploChIP and ASTQ results  
For validation of (a) HaploChIP and (b) ASTQ results, input and output material as well as genomic and cDNA were 
investigated for the presence of variant alleles at SNRPN rs705 (G/A) located within the transcript of the imprinted 
gene SNRPN. ∆CT values for SNRPN rs705 G (blue) and A (orange) alleles in output material and cDNA were 
significantly different to respective input and gDNA values, as expected for monoallelic gene expression.  
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3.1.6. Sequencing of the CD14 gene and flanking 5´ and 3´ prime region 
Furthermore, to address the question of whether any undetected SNP within the CD14 gene might 
influence ser5-P RNAPII binding to the promoter, PCR products of the CD14 gene and flanking 5´ 
and 3´ region from 10 individuals heterozygous in CD14 rs2569190 (partly taken from the larger 
cohort of 42 healthy Caucasians) were sequenced (Fig. 24) (see 2.4). First, two mixtures of CD14 
PCR products from each of 5 heterozygous individuals were sequenced. Both mixtures showed at 
least two possible unknown variant positions within the promoter region (Fig. 18a). Next, 
sequencing of single amplification products of the 5´ region of the CD14 gene from every 















mixture 1 mixture 2
a
b
Figure 18: Sequencing of the 
CD14 gene and nearby regions 
Cut-outs of the sequenced 
promoter region of the CD14 gene 
are given. (a) Sequence of the 5´ 
region of CD14 from two 
mixtures of PCR products from 
each of 5 different individuals 
heterozygous in CD14 rs2569190 
is shown. Two possible unknown 
variant positions located at 
positions -103 and -86 (from 
transcription start point) were 
detected and are indicated by 
arrows. (b) Sequence analysis of 
the 5´ region of the CD14 gene for 
each of the 10 single individuals 
revealed no unknown SNPs. 
Cut-outs were taken from 
analyses of sequencing data 
performed with the software 
Chromas LITE.  
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3.1.7. HaploChIP analysis with antibodies specific for ser5-P/ser2-P RNAPII - CD14 
rs2569190 allele-specific initiation of transcription but absence of allelic elongation in PBMC 
PBMC were found to contain CD14 rs2569190 within intron 1, indicating that this SNP might not 
have any influence on mRNA stability, at least in PBMC (Bregadze, 2010; Mertens et al., 2009). A 
more likely effect of this SNP on transcription factor binding can be hypothesised. It has been 
shown in reporter gene assays and EMSA by LeVan et al. that the T allele benefits transcriptional 
activity in monocytic cells by an enhanced affinity to the activating transcription factors Sp1 and 
Sp2 (LeVan et al., 2001). In vivo, this effect might be seen in a stronger binding of ser5-P RNAPII 
to T allele variants and thus a stronger transcription initiation of the CD14 rs2569190 T allele in 
PBMC.  
Preferential recruitment of ser5-P RNAPII does not result in a higher transcription of the preferred 
allele. As mentioned before, it is known that phosphorylation of CTD at the largest subunit of 
RNAPII is a key event during mRNA metabolism. The phosphorylation at serine 2 is essential for 
transcription elongation (Palancade and Bensaude, 2003). It seems that the very preferential 
recruitment of RNAPII, phosphorylated on serines at position 5, to CD14 rs2569190 T allele 
variants does not necessarily lead to fully phosphorylation on serines at position 2 and thus does not 
result in a higher transcription rate of the preferred allele. It was shown that the ser5-P RNAPII pre-
assembles to gene promoters in mammalians, but however, does not generate mature mRNA 
transcripts. The control of gene expression was shown to depend on the transition from transcription 
initiation to elongation by phosphorylation at serines 2 at the RNAPII (Hargreaves et al., 2009). 
To determine whether the CD14 polymorphism rs2569190 has any effect on ser2-P RNAPII and 
therefore on allele-specific transcription elongation, HaploChIP analyses were performed using H5 
and H14 (IgM) antibodies as well as a mock isotype (IgM) antibody. Therefore, an additional 
bridging step before precipitation of chromatin was necessary (see 2.3.2.). HaploChIP material was 
then subjected to RFLP running standard cycle number PCRs followed again by digestion reactions 
with HaeIII and TaaI and analysis with the 2100 bionanlyzer. Therefore, input and 
immunoprecipitated material of three different individuals, one (#2) only heterozygous in CD14 
rs2569190 and two (#6 and #7) double heterozygous (CD14 rs2569190, CD14 rs4914), was 
available (Fig. 19).  
As expected, control material (input and mock control) contained nearly the same amount of CD14 
rs2569190 T and C gene variants (T/C ratio 0.89-1.16) and H14-immunoprecipitated material 
showed again about twice the number of CD14 rs2569190 T variant fragments (T/C ratio 1.74-
1.94), also indicating in this experiment that there is a preferential binding of the ser5-P RNAPII.  
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In contrast, H5-captured chromatin exhibited similar amounts of CD14 rs2569190 T and C gene 
variants (T/C ratio 0.91-1.01) as did the mock control.  
More precisely, nearly no difference in the amount of CD14 rs2569190 variant fragments was 
detected in specific- (H5) and unspecific- (mock) captured material. These results indicate an 
absence of a preferential recruitment of the transcriptionally active RNAPII to the CD14 rs2569190 
variants or the respective CD14 haplotypes. These results reflect the findings on allelic CD14 
transcription in PBMC, at least as evidenced in two double heterozygous individuals (#6, #7; also 
same individuals as in (Mertens et al., 2009). 
 



















Figure 19: Differential recruitment of ser5-P and 
ser2-P RNAPII to the CD14 gene in PBMC 
HaploChIP analyses using antibodies directed 
against two phosphorylated isoforms of RNAPII for 
one individual heterozygous in CD14 rs2569190 
(#2) and for two donors double heterozygous in 
CD14 rs2569190 and CD14 rs4914 (#6, #7) are 
shown. Additionally, two homozygous controls (TT 
and CC) for complete and accurate digestion 
reactions are given. Enzymatic reactions with 
HaeIII are indicated in blue and with TaaI are 
marked in red (for fragment sizes representing T 
and C allele DNA see 2.3.3.2.) T/C ratios were 
calculated by given molarities and by taking 
hybrids into account. Complete experiments were 
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It was shown that HaploChIP analysis with the ser5-P H14 antibody confirmed the results generated 
by an IgG antibody specific for ser5-P RNAPII: a higher amount of CD14 rs2569190 T gene 
variants in immunoprecipitated chromatin from heterozygous individuals. But H5-captured 
material, on the contrary, showed no accumulation of specific fragments, nor did controls (input and 
mock material). Taken together, with expected T/C ratios ~1 for input and mock controls, highly 
SNP-specific restriction enzymes for the CD14 polymorphism rs2569190 and antibodies that are 
able to distinguish between the inactive and active form of the RNAPII the HaploChIP method was 
established as a successful tool for investigating the activity of different CD14 promoter variants, 
assessing both allelic transcription initiation and elongation in PBMC. 
 
Due to the intronic location of CD14 rs2549190 in PBMC from the healthy cohort, an effect on 
mRNA stability can be ruled out. As mentioned before, an influence on transcription regulation in 
terms of an enhanced affinity to transcription factor binding, shown by in vitro experiments (LeVan 
et al., 2001), is more likely. But also an effect of CD14 rs2569190 on an intron-mediated regulation 
of CD14 gene expression is possible. It is known that introns can play a role in eukaryotic gene 
expression by harbouring enhancer elements or alternative promoters (Rose, 2008).  
But based on the fact that the T allele of CD14 rs2569190, or the C-T-C-G haplotype, seems only to 
be advantageous for transcription initiation but not for transcription elongation, and the lack of an 
allelic CD14 gene expression imbalance in PBMC (Bregadze, 2010; Mertens et al., 2009), 
endotoxin sensing appears not to rely on a functional relevance of CD14 rs2561910 in PBMC.  
Regulatory variants can have inconsistent effects in different tissues (Pastinen and Hudson, 2004). 
It has been shown that CD14 is differentially expressed in monocytes and hepatocytes and that the 
latter contribute to sCD14 production (Pan et al., 2000). Thus, it appears more likely that the 
association of CD14 rs2569190 with higher sCD14 levels and lower IgE levels is due to an effect of 
the SNP in other cells lines, like non-myeloid cells, e.g. liver cells (Mertens et al., 2009).  
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3.2. Establishing and applying HaploChIP to assess the transcriptional activity of IRF-1 
rs2549009 promoter variants in a natural genomic context 
According to public databases, the IRF-1 gene shows a high genetic variability in various ethnic 
populations. For the Caucasian population there are 25 variant positions with a MAF >0.1 within 
the IRF-1 gene and 5´ and 3´ region known so far (NCBI). Some IRF-1 polymorphisms have been 
associated with various disease conditions in different ethnic populations. For example, intronic 
variations have been identified as linked to an altered susceptibility to human immunodeficiency 
virus 1 (HIV-1) infection in a Kenyan cohort (Ball et al., 2007). Further, a different set of 
polymorphisms within the IRF-1 gene, amongst others the IRF-1 rs2549009 (G/A) SNP within the 
promoter region, was found to be associated with HCV infection in Caucasians (Fortunato et al., 
2008; Saito et al., 2002; Wietzke-Braun et al., 2006) (Fig. 20). Thus, to address the question of 
whether the variant position IRF-1 rs2549009, located at position -300 from the transcription 
starting point, confers any functional impact on IRF-1 promoter activity, HaploChIP analyses were 













Figure 20: Schematic overview of the organization of the IRF-1 gene und transcript 
In humans, the IRF-1 gene is located on chromosome 5. The gene and the nearby 5´ and 3´ region include 25 variant 
positions with a MAF > 0.1 known so far for the Caucasian population (NCBI). The variant position IRF-1 rs2549009 
and the ASTQ marker SNP IRF-1 rs839 are indicated in light blue within the chromosome (a), the gene (b), and the 
transcript (c). Two other SNPs at position -410 (IRF-1 rs2549007) and -415 (IRF-1 rs2706384) that have been 
described as in a strong LD with IRF-1 rs2549009 (Saito et al., 2001) are marked in dark blue. Intronic variations that 
have been described as associated with different virus diseases are given in green (Ball et al., 2007; Fortunato et al., 
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Therefore, 13 healthy Caucasian blood donors were first of all genotyped at this variant position 
and IRF-1 rs2549009 heterozygous individuals (n=6) were used for the investigation of the allelic 
IRF-1 promoter activity. Genotype distribution was found to be in line with HWE (Tab. 3). Eleven 
of these 13 blood donors are part of a larger cohort of healthy Caucasians with available material 
from 41 donors that was used for further functional analyses of the transcriptional activity of the 









3.2.1. IRF-1 rs2549009 RFLP analyses with standard cycle number PCR 
Here, the HaploChIP technique was established and performed on formalin-fixed and enzymatically 
sheared chromatin available from 5 healthy IRF-1 rs2549009 heterozygotes. The question of 
whether IRF-1 rs2549009 has any functional impact on IRF-1 promoter activity was assessed by 
investigating the relative binding frequency of differentially phosphorylated RNAPII isoforms to 
IRF-1 promoter variants. (i) HaploChIP material was immunoprecipitated by the IgG antibody that 
is specific for ser5-P RNAPII. (ii) HaploChIP analysis was also performed by immunoprecipitation 
using the IgM antibodies that distinguish between transcriptionally inactive (H14) and active (H5) 
RNAPII and the mock isotype (IgM). For IgM antibodies, additional bridging between protein G 
magnetic beads and an anti-IgM-specific IgG antibody was necessary before precipitation of 
chromatin (see 2.3.2.). Antibody-captured and non-immunoprecipitated (input) chromatin was 
subjected to RFLP; this process included amplification (40-45 cycles) spanning a region around 
IRF-1 rs2549009, followed by digestion reactions of PCR products and analysis of digested 
material with the 2100 bioanalyzer. The software NEBcutter V 2.0 was again used to identify SNP-
specific endonucleases.  
MvaI, which recognizes and digests a DNA sequence containing IRF-1 rs2549009 A, was found, 
while BcnI was observed to be specific for a DNA sequence containing the IRF-1 rs2549009 wild-
type G (see 2.3.3.2.). For control of accurate digestion reactions, RFLP analyses were additionally 
performed using gDNA from individuals homozygous for the IRF-1 rs2549009 wild-type and the 
variant allele.  
Tab. 3: Genotype distribution among 13 healthy Caucasian blood donors
rs2549009 [G/A]
homozygous
GG MAF p 
a
6 (46.2%) 1 (7.6%)6 (46.2%) 0.308 1.00





3. Results & Discussion 45 
 
(i) Input material contained, as expected, nearly the same amount of IRF-1 rs2549009 A and G 
promoter variants (A/G ratios 1.00 ± 0.01 – 1.11 ± 0.03). But output material, that was 
immunoprecipitated by the IgG antibody directed against ser5-P RNAPII, exhibited a higher 
amount of IRF-1 rs2549009 A promoter variants (A/G ratios 1.24 ± 0.01 – 2.11 ± 0.31) in all 
























Figure 21: HaploChIP analysis of the IRF-1 rs2549009 promoter activity  
(a) Formalin-fixed and enzymatically sheared chromatin from 5 healthy individuals, heterozygous in SNP IRF-1 
rs2549009, was immunoprecipitated with an antibody directed against ser5-P RNAPII. Non- and immunoprecipitated 
chromatin was subjected to amplification spanning a region around IRF-1 rs2549009. Products of 142bp in size were 
digested by two different restriction enzymes, MvaI and BcnI. Digestion with MvaI is indicated in red, while digestion 
with BcnI is shown in blue (Fragment sizes see 2.3.3.2.). Digestion analyses were carried out in a bioanalyzer. Material 
from homozygous individuals (AA and GG) is shown as controls for complete and specific enzymatic activity. (b) 
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(ii) Controls for accurate digestion with MvaI and BcnI showed digested fragments of expected size. 
Input and mock (IgM) control-captured material showed, as expected, almost no difference in IRF-1 
rs2549009 A and G promoter variants (A/G ratio 0.98 – 1.08). In all H14-captured material, the 
transcriptionally inactive ser5-P RNAPII was again found to preferentially bind the IRF-1 
rs2549009 A allele (A/G ratio 1.22 ± 0.08 – 1.40 ± 0.05) (see publication 6.2., page 71; Mertens et 
al., 2010). In contrast, the ratio of A and G promoter variants in H5-captured material was found to 
vary between 0.79 ± 0.01 (individual #1) and 1.24 ± 0.02 (individual #9). Some donors (#8; #10) 
showed almost no difference (A/G ratio 0.96 ± 0.04; 1.05 ± 0.05) in the amount of IRF-1 rs2549009 
A and G promoter fragments, while other individuals were found to exhibit a higher amount of the 






















Figure 22: HaploChIP analysis of the IRF-1 rs2549009 promoter activity: H5 antibody specific for ser2-P RNAPII 
(a) Immunoprecipitation by H5 antibody was conducted on chromatin from 5 healthy donors heterozygous in IRF-1 
rs2549009. HaploChIP material was subjected to RFLP; this included amplification spanning a region around IRF-1 
rs2549009 and digestion of PCR products. Digestion reactions were performed using MvaI (red) and BcnI (blue), 
followed by analysis of fragments in a bioanalyzer. IRF-1 rs2549009 A/G ratios were calculated by given molarities for 
each fragment by the 2100 bioanalyzer software. Accurate digestion reactions were controlled by material from IRF-1 
rs2549009 homozygous individuals (AA and GG) that was additionally subjected to RFLP. For fragment sizes see 
2.3.3.2. (b) Experiments were performed at least twice. Mean ratios and standard deviations are given (Modified from 
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As expected, input and mock controls always showed A/G ratios of ~1, as did also the controls (AA 
and GG material) for accurate and specific digestion reactions, which exhibited only, as expected, 
fragments of expected size in all samples tested. These controls showed that immunoprecipitation 
by H14, H5 and IgG antibodies, despite the additional bridging step for H14 and H5, was specific. 
Additionally, RFLP analysis was performed using highly IRF-1 rs2549009 SNP-specific 
endonucleases, MvaI and BcnI. Thus, the HaploChIP method was established successfully as a tool 
to investigate the activity of the IRF-1 rs2549009 promoter variants by distinguishing 
phosphorylated isoforms of the RNAPII during the transcription cycle.  
 
The HaploChIP results show a preferential binding of the transcriptionally inactive RNAPII to IRF-
1 rs2549009 A promoter variant, but no preferential recruitment of the ser2-P enzyme to the one or 
the other IRF-1 rs2549009 promoter variant. This indicates that the IRF-1 rs2549009 A promoter 
variant may be advantageous for transcription initiation, but an allelic IRF-1 transcription 
elongation seems not to be solely controlled by this promoter polymorphism in PBMC (Mertens et 
al., 2010). The observation of a donor-dependent allele-specific ser2-P RNAPII activity is 
compatible with in vitro findings on IRF-1 promoter activity showing stronger promoter activity 
either of the one or the other allele, depending on the system. Saito et al. showed a stronger 
induction of gene expression for the IRF-1 rs2549009 variant allele A in unstimulated or IFN-
stimulated PLC/PRF/5 hepatoma cells, while less activity of a gene construct carrying the IRF-1 
rs2549009 A allele was found in ionomycin-stimulated Jurkat T cells by Schedel and colleagues 
(Saito et al., 2001; Schedel et al., 2008).  
 
3.2.2 Correlation between allele-specific IRF-1 rs2549009 promoter activity and allelic 
transcription of IRF-1 in PBMC 
A donor-dependent preferential recruitment of the ser2-P RNAPII to the IRF-1 rs2549009 promoter 
variants was shown with HaploChIP experiments, indicating differential allelic IRF-1 gene 
transcription elongation. Thus, it was also expected to find an allele-specific imbalance of gene 
expression in IRF-1 transcripts. The relative amount of allelic transcripts was therefore quantified 
using IRF-1 rs839, located within IRF-1 exon 10, as a marker SNP for ASTQ (Fig. 20). Assessing 
allelic IRF-1 transcripts to respective IRF-1 rs2549009 promoter variants haplotyping was 
performed on a total of 41 healthy Caucasians. Two independent read out assays for ASTQ 
analysis, (i) differently labelled allele-specific 5´nuclease assays and (ii) RFLP analyses, were 
conducted on material from IRF-1 rs839 heterozygous individuals.  
 
3. Results & Discussion 48 
 
Genotype distribution of IRF-1 rs839 was found to be in line with HWE, and MAF (0.366) was 
found to be close to that given at NCBI. On the basis of these findings, LD was calculated using the 
software HaploView version 4.1. With D´= 0.947 and r2 = 0.897 the IRF-1 exon 10 SNP rs839 was 
found to be a suitable polymorphism for assigning IRF-1 transcripts to respective IRF-1 rs2549009 
promoter variants. The wild-type alleles G and variant alleles A for both SNPs, IRF-1 rs2549009 
and IRF-1 rs839, were found to be in a high LD (Mertens et al., 2010). 
Some of the 16 IRF-1 rs839 heterozygous individuals showed an allelic expression imbalance for 
IRF-1 mRNAs. (i) The rs839 A/G ratios varied from 0.84 ± 0.04 (donor #12) to 1.13 ± 0.13 (donor 
#9) and similar results were detected by (ii) RFLP, where IRF-1 rs839 A/G ratios varied between 
0.87 and 1.06. Linear regression analysis of data derived from the two different read out assays 
revealed a close correlation with p = 0.003 and r = 0.71. These results provide first evidence for a 
bidirectional IRF-1 gene expression imbalance in PBMC (ASTQ experiments were performed by 
our research team members; Mertens et al., 2010).  
Further, the relative proportion of IRF-1 rs2549009 promoter variants bound to the transcriptionally 
active ser2-P RNAPII was found to correlate significantly (p = 0.0022; r = 0.99) to respective 
allele-specific IRF-1 transcripts (Fig. 23). In detail, donor #9 showed an IRF-1 rs2549009 A/G ratio 
of 1.22 in H5-immunoprecipitated material, indicating a preferential binding of the transcriptionally 
active RNAPII to the IRF-1 rs2549009 A promoter variant. The same donor also exhibited an IRF-1 
rs839 A/G transcript ratio of 1.13 in PBMC. Donors #1 and #4 showed higher amounts of both IRF-
1 rs2549009 G promoter variants (IRF-1 rs2549009 A/G ratio 0.80; 0.86) and respective IRF-1 
rs839 G transcripts (IRF-1 rs839 A/G ratio 0.92; 0.90). Almost no difference in the amount of 
allelic IRF-1 promoter variants and respective transcripts were found in PCMC from donors #8 and 
























































ts Figure 23: Close correlation between IRF-1 rs2549009 
promoter variants and respective IRF-1 rs839 
transcripts  
The relative binding of the active ser2-P RNAPII to IRF-
1 rs2549009 promoter variants was found to correlate 
significantly to respective allelic IRF-1 transcripts in 
PBMC from 5 healthy double-heterozygous (IRF-1 
rs2549009, IRF-1 rs839) Caucasians (Modified from 
Mertens et al., 2010). 
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The relative binding frequency of the transcriptionally active RNAPII to IRF-1 promoter variants (i) 
does not seem to be solely dependent on IRF-1 rs2549009 variants and (ii) was found to correlate to 
respective IRF-1 transcripts in freshly isolated PBMC from healthy Caucasians. These provide 
evidence for an IRF-1 gene expression imbalance that does not appear to be solely controlled by the 
IRF-1 rs2549009 promoter variant in PBMC.  
Allelic gene expression has been shown for up to 5% of human autosomal genes (Pastinen et al., 
2005) and whole genome linkage studies of total gene expression have suggested that 1-3% of 
human genes harbour common cis-acting variants (Buckland, 2004; Rockman and Wray, 2002; 
Serre et al., 2008). The small bidirectional imbalance in allele-specific IRF-1 promoter activity and 
gene transcription, assessed by HaploChIP and ASTQ, was found to be dependent on the respective 
donors. This finding is quite in accordance with observations by others. It has been reported that 
imbalances of a particular gene may only occur in some individuals (Buckland, 2004; Rockman and 
Wray, 2002). Further, also the ranges of allelic imbalances were found to vary a lot, not only 
between genes but also between individuals. Differences of less than 10% to 4.3-fold or higher have 
been reported (Buckland, 2004; Serre et al., 2008; Southam et al., 2007; Yan et al., 2002). 
 
3.2.3. Further functional studies on IRF-1 rs2549009 gene expression 
A parallel analysis of total IRF-1 gene expression revealed that total IRF-1 gene expression was not 
significantly different when related to IRF-1 rs2549009 promoter genotypes (p = 0.2709) in 41 
healthy Caucasians. A more detailed analysis within the group of 16 individuals heterozygous in 
IRF-1 rs2549009, however, revealed a close and positive relation (p = 0.0035, r = -0.68) between 
the relative amount of G allele transcripts and total IRF-1 mRNA levels in PBMC (these analyses 
were done in cooperation with our research team members; Mertens et al., 2010).  
 
3.2.4. LD between IRF-1 rs2549009 and neighbouring promoter polymorphisms 
The bidirectional allele expression imbalance in IRF-1 rs2549009 heterozgotes (Mertens et al., 
2010) indicates a gene expression regulation that is not solely controlled by IRF-1 rs2549009. IRF-
1 gene expression might be regulated by other genetic variants in cis or might be influenced by yet 
unidentified gene-environment interactions in trans (Mertens et al., 2010).  
Two other SNPs, IRF-1 rs2549007 and IRF-1 rs2706384 located 110 nt and 115 nt upstream of 
IRF-1 rs2549009 within the IRF-1 promoter region, have been described by Saito et al. as being in a 
high LD with IRF-1 rs2549009 in a Japanese population (Saito et al., 2002).  
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To address the question of whether these two SNPs might have any cis-regulatory relevance for 
IRF-1 gene expression in Caucasians, geno-/haplotyping was performed on gDNA samples from 40 
individuals of the healthy cohort.  
Genotype distribution of IRF-1 rs2549007 among the large healthy cohort was found to be in line 
with HWE, also MAF of IRF-1 rs2549007 was found to be similar to IRF-1 rs2549009 (see 3.2. and 
Tab. 4). On this basis LD was calculated again using the software HaploView version 4.1 and with 
D´= 1.0 and r2 = 0.947, these two SNPs were evaluated as being in a high LD. Therefore, any 
observations that were made for IRF-1 rs2549009 might be as well attributed to IRF-1 rs2549007 
(Mertens et al., 2010).  
Genotype distribution of IRF-1 rs2706384 was also found to be in line with HWE and MAF of IRF-
1 rs2706384 was found to be similar to IRF-1 rs2549009 (see 3.2. and Tab. 4) among the healthy 
cohort. Allelic LD for IRF-1 rs2549009 and IRF-1 rs2706384 was also calculated on this basis 
using the software HaploView version 4.1 and found to be close (D´= 0.926; r2 = 0.604). Thus, 
observations made for IRF-1 rs2549009 seem to be attributable to IRF-1 rs2706384 as well 











As expected, the two IRF-1 promoter SNPs rs2549007 and rs2706384 were found to be in a close 
LD to IRF-1 rs2549009 in our cohort, as well. Thus, at least an impact of these two other SNPs on 
IRF-1 gene expression can be ruled out.  
A contribution of gene-environment interaction to IRF-1 rs2549009-dependent gene expression is 
supported by comparing IRF-1 gene expression with its inducibility by IFN-α in ex vivo-derived 
PBMC from healthy and HCV-infected individuals (Mertens et al., 2010).  
As mentioned before, IRF-1 mRNA expression levels were not related to IRF-1 rs2549009 
promoter genotypes in healthy individuals (see 3.2.3.).  
 
Tab. 4: Genotype distributions among the healthy Caucasian cohort
rs2549007 [G/A]
rs2706384 [A/C]
ww vvwv MAF p a
18 (45.0%) 7 (17.5%)







a p exact test for Hardy-Weinberg equilibrium
w = wild-type; v = variant
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Also gene expression levels in ex vivo-derived PBMC from patients with chronic HCV infection 
were not found to be significantly different when compared to IRF-1 rs2549009 genotypes. But 
total IRF-1 mRNA levels in PBMC from chronic hepatitis C patients were significantly higher than 
in healthy individuals (Aidery, 2010). However, responsiveness of IRF-1 gene expression in PBMC 
to human recombinant IFN-α in vitro was found to be significantly higher in healthy individuals 
and, interestingly, more pronounced in IRF-1 rs2549009 AA homozygotes (Aidery, 2010).  
Thus, the findings of a positive relation of allelic and total IRF-1 gene expression (Aidery, 2010; 
Mertens et al., 2010) suggests a biological impact of IRF-1 rs2549009 on IRF-1 gene expression, 
that seems also to be controlled by a positive or negative regulation in trans (Mertens et al., 2010).  
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4. Summary 
The IRF-1 promoter SNP rs2549009 and the variant rs2569190 within the CD14 gene have been 
described as being associated with various disease conditions. In vitro experiments (EMSA; 
reporter gene assays) showed that the T allele of CD14 rs2569190 favours transcription factor 
binding and that DNA elements containing the respective variant allele promote gene transcription. 
The IRF-1 rs2549009-carrying DNA element induces allele-specific constitutive expression levels 
of a luciferase reporter in various cell lines. To determine whether these SNPs confer any functional 
effect on transcriptional activity in their natural genomic environment, analyses of allele-specific 
promoter activities were conducted by applying HaploChIP on ex vivo-derived PBMC. Therefore, 
antibodies were used that are directed against ser5-P and ser2-P isoforms of RNAPII that reflect 
binding and enzymatic activity at initiation and elongation stages of the transcription cycle, 
respectively.  
Ser5-P RNAPII was found to be preferentially recruited to the variant alleles of CD14 rs2569190 as 
well as of IRF-1 rs2549009, results that are in line with those from the above-mentioned in vitro 
experiments.  
The active RNAPII, on the contrary, was found to not be preferentially bound to the wild-type or 
variant allele of CD14 rs2569190. This finding is supported by (i) the absence of a CD14 mRNA 
expression imbalance and (ii) the absence of any relation of three other SNPs within the CD14 gene 
and allelic gene expression. Sequencing of the CD14 gene also failed to reveal any so-far unknown 
SNP that could influence CD14 promoter activity. The genetic variant CD14 rs2569190 thus might 
be advantageous for transcription initiation. Endotoxin sensitivity associated with this 
polymorphism, however, does not appear to rely on allele-specific CD14 gene transcription at least 
in PBMC (Mertens et al., 2009).  
Regarding IRF-1 rs2549009, a preferential binding of the ser2-P RNAPII to the G or A promoter 
variants or binding without any preference - depending on the donor - was observed in PBMC from 
healthy Caucasians. This finding actually accords with the varying results from different reporter 
gene assays and may explain the variance. Furthermore, the relative binding frequency of the active 
RNAPII to IRF-1 rs2549009 promoter variants was found to be closely related to the relative 
amount of allele-specific IRF-1 transcripts. These results provide evidence for a bidirectional IRF-1 
gene expression that does not appear to be solely controlled by IRF-1 rs2549009 in cis, but may 
rely on a yet undetected polymorphism or haplotype or on environmental control in trans (Mertens 
et al., 2010).  
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forward primer                                             5´ CTA GAT GCC CTG CAG AAT CCT  3´ 
reverse primer                                              5´ CCC TTC CTT TCC TGG AAA TAT TGC A  3´                         
probe T                                                 VIC 5´ CCT GTT TAC GGT CCC CCT  3´ 
probe C                                               FAM 5´   CT GTT TAC GGC CCC CCT  3´ 
rs5744455 (C/T) 
rs574 tetra T f                                              5’ AAG GAA GGG GGA ATT TTT CTT TAG CCT 3’ 
rs574 tetra C r                                             5’ GGT AGA ATT AGG TTC AAG AAA AGG AAG GTG 3’ 
rs574 tetra for                                              5’ CTG AGC AAC AGA GCA AGA CTC TAT CTC A 3’ 
rs574 tetra rev                                              5’ CAT TTC TTT GAC TTC TTC CTT GTC TTG G 3’ 
rs2563298(G/T)  
rs2563 tetra T r                                            5’ TAA AGG TCT GTT AAA TGA ATG ACA CGA AA 3’ 
rs2563 tetra G f                                            5’ CCC ACC TTT ATT AAA ATC TTA AAG AAC AGG 3’  
rs2563 tetra for                                            5’ TTT GCC TAA GAT CCA AGA CAG AAT AAT G 3’ 
rs2563 tetra rev                                            5’ TTT CTT AGG GAG TTA GGA TGA AGA AAG C 3’ 
IRF-1 
rs2549009 (G/A)  
forward primer                                              5´ GGA CAA GGC GGA GTG AGA  3´ 
reverse primer                                               5´ GGC TGC CCG GGA CAG  3´     
probe A                                               FAM 5´ CCC CTG GCC CCA G  3´ 
probe G                                                 VIC 5´ CCC CCG GCC CCA G  3´                                                   
rs2549007 (G/A)  
forward primer                                              5´ AGG CTT TCT GCC TTC TTC ACT T 3´ 
reverse A primer                                           5´ GGT ATA TCT CCC GAA CGC ATG T 3´     
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rs2706384 (A/C)  
reverse primer                                               5´ CTG TCC TCT CAC TCC GCC TTG TCC  3´     
forward C primer                                          5´ CAA GTG CCC GGG CGA CCC  3´ 
forward A primer                                          5´ CAA GTG CCC GGG CGA CCA  3´ 
SNRPN 
rs705 





primer for RFLP analysis 
rs2569190 for                                              5´ GACACAGAACCCTAGATGCCCT 3´    
rs2569190 rev                                              5´ GTGAACTCTTCGGCTGCCTC 3´ 
 
enzymes for RFLP analysis 
TaaI  allele T        5´ ACN↓GT 3´   
         3´ TG↑NCA 5´ 
    
HaeIII  allele C        5´ GG↓CC 3´  
         3´ CC↑GG 5´  
IRF-1 
primer for RFLP analysis 
IRF rs254 for                                               5’ CAG GAG GGT GAA AAG ATG GCC  3´ 
IRF rs254 rev                                              5’ CGA GCG CTC CCA ATC CAC  3´ 
enzymes for RFLP analysis 
            
    
  MvaI allele A                                               5´ CC↓AGG 3´    
                                              3´    GGT↑CC 5´ 
 
BcnI  allele G                                            5´ CC↓CGG 3´   
                                 3´  GGG↑CC 5´ 
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5.3. Sequencing  
CD14 
primer for region 1 
for1                                                              5’ GCC GAG ATC ATG GCA 3’  
rev1                                                             5’ ACC CTG ATC ACC TCC CCA C 3’ 
primer for region 2 
for2                                                              5’ CCC CTC CCT GAA ACA TCC TT 3’ 
rev2                                                             5’ GAG TGT GCT TGG GCA ATG CT 3’ 
primer for region 3 
for3                                                              5’ GGA CTT GCA CTT TCC AGC TTG 3’ 

























Figure 24: Sequenced region of the CD14 gene and SNP positions within the gene and transcript 
CD14 sequence and SNP information are taken from ensemble (ENSG00000170458) and NCBI. Transcribed region 
(transcript variant 1: NM_000591.2) is indicated in orange. Flanking sequencing primers are given in grey and 
overlapping regions are marked in yellow. Known polymorphisms are given in green, while SNPs with a MAF > 0.1 
are additionally marked in blue. During sequencing of 10 different CD14 rs2569190 heterozygous individuals possible 
unknown variant positions within the promoter region were detected and are indicated in red. 




Allele-specific primer rs5744455 (C/T) 
rs574 tetra T f                                              5’ AAG GAA GGG GGA ATT TTT CTT TAG CCT 3’ 
rs574 tetra C f                                              5’ AAG GAA GGG GGA ATT TTT CTT TAG CCC 3’ 
CD14 tetra 3-rev                                          5’ TTT TCT TGA GGA GGA CAG ATA GGG TTT C 3’ 
Allele-specific primer rs2569190 (C/T) 
rs2569190 T f                                              5’ AAG GAA GGG GGA ATT TTT CTT TAG CCT 3’ 
rs2569190 C f                                              5’ AAG GAA GGG GGA ATT TTT CTT TAG CCC 3’ 
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This study was designed and supervised by SM and GR. JM established and performed HaploChIP 
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designed the figures and RB prepared the tables. HB carried out the statistical analyses.  
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